question manag team
list relev question
ahead annual credit suiss healthcar confer compil
respect
manag team across divers coverag univers healthcar
compani pleas reach team copi latest model
request prepar meet scottsdal arizona
topic discuss
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
tabl content
labcorp america lh
interpret presid blueprint around lower drug price
pocket spend administr price
propos might propos impact propos think
like implement follow elect
see long-term outlook agn top-line growth given
chang seen busi past coupl year still
challeng outlook next month
much price growth assum botox juvederm think
growth outlook
sever botox competitor work seem differenti
profil dysport xeomin offer enter market
strategi maintain share face addit brand competit
announc work toward biosimilar botox
commerci impact may far away think risk aesthet
therapeut franchis biosimilar botox enter market futur
investor disappoint coolsculp perform walk
dynam impact longer term expect
recent medic aesthet day consider amount time spent
ex-u opportun pursu aggress
think ad ex-u sale meaning enough drive
needl compani allergan size
see botox therapeut sale impact recent entri
anti-cgrp antibodi migrain patient prefer botox date
give confid liver safeti profil ubrogep acut migrain
accept enough allow regulatori approv expect product
compet gener triptan well lli lasmiditan
given cgrp antibodi allow infrequ dose monthli quarterli
percent market think would will take medic everi
day even oral product like atogep oppos inject
expand see commerci outlook cenicriviroc cvc
follow data date product nash market get develop
help build market
fda approv esmya
product would make sens stop develop product complet
point given continu invest need like limit commerci potenti
next step
reason expect abicipar await data next-
gener formul inform new formul would make
product label much inflamm accept real world
plan hold back launch product next gener formul
avail avoid physician neg initi experi product
much commerci opportun iv formul rapastinel
statu oral formul see data product
given price pressur see linzess import data
indic addit abdomin symptom franchis
interpret presid blueprint around lower drug price
pocket spend administr price
propos might propos impact bristol propos think
like implement follow elect
proceed stay contact fda regard checkmate-
studi expect provid updat ahead may pdufa
someth might requir fda advisori committe meet
work fda regard tmb approv endpoint
see tmb test fit market could replac test specif
target like could biomark work togeth defin treatment
popul step take think need take order
drive tmb adopt especi amongst community-bas oncologist outsid
us
see keytruda approv nsclc impact market potenti
opdivo/yervoy nsclc difficult gain traction even
given head start merck market
much ad efficaci opdivo yervoy combo need show
monotherapi chemotherapi gain broad adopt
percentag melanoma market rel keytruda
percentag melanoma use oppos
monotherapi key factor think market share
breakdown melanoma compar might see nsclc
latest eu statu potenti get approv nsclc
rcc
renal cell initi market reaction opdivo yervoy
combo envis combo hold face posit data
base combin
main i-o indic excit next year
period outsid lung renal melanoma peopl focus
area besid i-o think investor underappreci
think bristol outlook next year
expect futur eliqui growth given potenti impact
disappoint marin
command import avail factor xa antidot portola
andexxa boost growth factor xa inhibitor class gener eliqui
xarelto
initi thought commerci potenti inhibitor given
crowd psoriasi market
initi thought nash market seen
interest scientif develop think investor still wonder new
market creat
interpret presid blueprint around lower drug price
pocket spend administr price
propos might propos impact lilli propos think
like implement follow elect
latest see around price pressur diabet franchis
part franchis see pressur expect
play rel
posit rewind result think impact trulic
much diabet market think product may abl
captur think uptak rel uptak saw
much sale trulic class come primari care
physician compar endocrinologist trulic market share rel
victoza differ pcp endocrinologist
alway bullish outlook market
think given posit rewind data along oral
co-agonist potenti enter market next sever year
current assumpt around ozemp potenti oral semaglutid
might impact inject market trulic specif
thought point generic/biosimilar version victoza
might disrupt market arriv
provid addit insight plan improv toler
obtain insight go adjust
thing phase program
lilli think invest innov diabet alway hear
much price pressur may stifl innov diabet see lot price
pressur still see interest innov
humalog franchis start face pressur biosimilar
impact biosimilar similar differ seen basal market
lantus/basaglar
basaglar done well date see longer term opportun
franchis biosimilar version insulin glargin potenti enter
market mani biosimilar expect
patient popul verzenio gain traction first much total
address market verzenio base current indic alreadi
penetr ibranc
updat expect around olumi us
see taltz compet cosentyx psoriasi beyond
market cgrp inhibitor develop emgal fit
pictur lasmiditan acut migrain treatment market
compet gener triptan oral cgrp
reason expect tanezumab seen phase
data data still come
interpret presid blueprint around lower drug price
pocket spend administr price
propos might propos impact propos think
like implement follow elect
adjust commerci infrastructur account
biosimilar competit remicad latest expect around
think impact biosimilar us next month much
fact remicad infus administ medic set
impact fend biosimilar oppos
drug self-administ
stelara shown strong growth much crohn indic
much indic psoriasi psoriat arthriti
entri impact stelara use psoriasi psoriat arthriti
tremfya uptak strongest date patient use
patient alreadi tri tnf move tremfya
expect tremfya well develop impact
stelara posit market expect head head trial
taltz expect read
vocal believ payer relationship built
humira help gain rapid formulari access risankizumab
well upadacitinib seem reason would off-set
impact risankizumab might tremfya
invokana lose signific share jardianc follow releas
empa-reg canva studi result way either plan
turn around addit effort on-going better understand
safeti profil class determin amput risk realli class risk
compass data encourag futur uptak xarelto
marin command discuss market opportun
xarelto overal see initi adopt xarelto compass
see futur growth imbruvica darzalex come
discuss decis pursu legend deal see impact
car-t futur
esketamin uniqu product uniqu commerci opportun also
challeng think potenti product specif
initi uptak curv assum obtain approv
concern amongst investor near end strong
product stori may difficult maintain level growth seen
recent next sever year market pipelin product like
compani evalu differ busi develop opportun across
three differ segment compar priorit
interpret presid blueprint around lower drug price
pocket spend administr price
propos might propos impact merck propos think
like implement follow elect
impact commerci date recent posit keynot trial
readout nsclc much new patient share obtain
nsclc market step put place hold lead
nsclc given multipl competitor close behind
thought tumor mutat burden endpoint includ
endpoint current futur trial tmb data
share necessari blunt effort
merck thought variou novel immuno-oncolog mechan
develop one excit investor
appear gener disappoint seen merck other
recent medic meet follow-on i-o mechan
think street assign adequ valu lynparza
anticip addit benefit lynparza keytruda keytruda alon
indic think see addit benefit
combo made attract payer sinc two compani work togeth
set price combin
see key area lenvima alon combin
keytruda potenti expect collabor
go forward oppos outright acquisit
indic within immuno-oncolog yet given regulatori
approv excit clinic perspect
gardasil continu outperform driven use newer popul
countri market opportun product look year
januvia obvious larg franchis steglatro market
els on-going term innov diabet
co-agonist glucagon receptor product current
hold diabet area expect invest
besid keytruda driver possibl upsid next year
think busi develop highlight innov key driver
drive decis make balanc need near-term
growth need long-term growth opportun
expect
next
year could see take anoth look whether make sens
sell spin anim health next year two
anim health divis
given evolv busi model primari care focu specialti
care/oncology/vaccin
expect compani
latest around ceo stay sinc ken frazier longer
step ceo end open compani
go forward plan unchang
interpret presid blueprint around lower drug price
pocket spend administr price
propos might propos impact propos think
like implement follow elect
see commerci potenti tafamidi seen
phase data reason uptak curv product like still
need build diseas awar grow market
reason expect tanezumab follow recent phase data
confid safeti concern identifi previous
suffici address potenti product greater osteoarthr
chronic low back pain given question around rpoa tjr patient oa
built pretti strong gene therapi presenc assum
area continu focu busi develop perspect satisfi
portfolio confid dmd gene therapi
program see data expect see
comfort bavencio clinic profil competit
far ahead develop across variou indic
need access better succeed immuno-oncolog
think bavencio key differenti factor go forward
think indications/combin data next
see potenti talzenna talazoparib follow embarca
data space quit competit agent much broader
develop program area potenti
ibranc lot focu move product addit line
therapi breast cancer develop perspect see
biggest risk show posit data patina penelop palla see
data next year growth outlook product
studi posit
differenti
vizimpro given
tagrisso/flaura data egfr mutant nsclc
see commerci opportun xtandi given expand label
also take account competit erleada like competit
gener version zytiga come month
vaccin clostridium difficil staph aureu two investor may
overlook walk develop program
patient popul think might like benefit one
sever follow jak develop behind xeljanz differ
see potenti
focu term might larger deal back
consider key factor consid decid
consum busi ceo transit impact
corpor strategi
thought palisad data feedback
allergist thought safeti profil
detail mani patient palisad
discontinu therapi need use epinephrin expect around
hypersensit eoe data compar expect
base palisad data chanc initi label
includ patient older patient age includ initi label
think abl expand label includ patient
addit inform hope receiv on-going phase
actual instruct given patient term
take given dose limit around exercis etc
food challeng implement real world
updat think price product like given
cure peanut allergi help desensit patient
thought dbvt data see role viaskin peanut
market much see two compani need work togeth
oppos battl knock one
see like impact combin dupix
think help drive stronger efficaci patient help minim
toler issu seen expect combin
like posit impact children adult earli say
main object nestl collabor decis
extend made drive decis perspect
expect addit collabor player beyond nestl
talk littl biomark strategi could
incorpor real world
good proxi market opportun
updat program beyond
would make sens pursu partnership even sale compani
given effort take success commerci
new ceo chang compani focus develop
eptinezumab otherwis hope reshap compani
seen anti-cgrp antibodi launch feel
eptinezumab differenti agent plan gain
meaning share fourth market
thought oral anti-cgrp drug develop
particularli one prophylact use success might impact
market opportun antibodi
think consid clinic meaning migrain prophylaxi
therapi much headach improv think need show
payer reimburs product
expect anoth updat self-administr program
see advantag intramuscular approach subcutan approach
compar
big could iv formul self-administr option
go along discuss econom incentives/disincent might
work patient physician decid self-administr
intraven formul expect total pocket cost
patient receiv infus eptinezumab
walk us commerci strategi mani sale rep
need promot eptinezumab target answer around
chang see recent launch cgrp need
gain market share
expect patient need go off-label therapi botox
abl get onto anti-cgrp think would consid
failur prior therapi
cash burn expect long take next
talk antibodi product platform gross margin
could vs margin seen antibodi manufactur
exampl compani use yeast base approach similar
obtain fda approv
thought commerci eptinezumab ex-u larger
much ad invest plan make vivitrol hope reacceler
growth product
breakdown prescript vivitrol across variou payer
longer term project vivitrol chang given public outcri
opioid addit call addit fund issu benefit vivitrol
expect signific impact
given neg fda advisori panel adjunct depress
compani think asset event complet respons
letter fda would alkerm conduct addit studi
event alkerm choos abandon would absenc
product impact implic futur gross margin
relev line item would urgenc slow spend acceler
key controversi around commerci think
commerci product assum patient tri
gener olanzapin first start gain weight allow
shift think metabol paramet mention
much impact patient provid payer think valu
proposit
see market potenti multipl sclerosi
much think global long-act inject antipsychot lai market
grow next year talk key driver
aristada fare competit landscap see aristada
fit especi face trinza much impact
think everi month formul make uptak
new initi dose impact aristada use far
latest thought potenti assum
potenti asset think move forward given oncolog
area focu may take signific amount invest
properli develop particularli large-cap pharma compani
appear player healthcar industri focus effort
rare/orphan diseas focus pipelin central nervou
system disord drug comment strategi given
challeng seen success develop drug condit
call compani indic look bring new candid
clinic would abl share us kind molecul therapeut
categori oncolog other
given strong balanc sheet latest capit deploy prioriti
acquir pipelin candid someth might consid go forward
thought long-term oper margin expans potenti given
signific invest make sg
breakdown prescript vivitrol across variou payer
describ enter hyperoxaluria market world-wide
differ form hyperoxaluria typic diagnos
difficulti reach correct diagnosi
current treatment option avail patient enter hyperoxaluria
effect
longer term implic diseas untreat exist treatment
ineffect
provid detail recent discuss fda give
confid fda final protocol statist plan phase
studi reloxalias treat enter hyperoxaluria way
abl start trial year end
addit posit clinic meaning phase studi
gate factor file nda reloxalias
pharmacoeconom argument payer pay treatment
ip protect reloxalias
indic enough cash take
assumpt behind guidanc guidanc assum addit phase
trial beyond
think cadenc cash burn capit expenditur
key catalyst rest
latest timelin around remain phase program filgotinib
expect see result safeti studi look high dose
male assum remain gate factor regulatori submiss
expect submiss occur
indic pursu filgotinib
confid mechanist standpoint
confid filgotinib program answer question regul
might dose side given surpris seen regulatori
review tofacitinib baricitinib
see effect platelet patient use filgotinib addit could
pleas discuss latest dvt/pe event rate filgotinib program
filgotinib newer indic pursu
confid mechanist standpoint
see upadacitinib stack potenti competitor filgotinib
across variou indic filgotinib differenti jaki
character opportun ipf drug
would fit within current treatment paradigm base data
releas date flora studi
regard could pleas explain feel confid move asset
registr trial directli provid detail studi design
divest cystic fibrosi asset chang
compani think regard develop program rational
restructur cf agreement
came market fund follow releas posit data
filgotinib even though suffici cash would provid rational
strategi behind rais
filgotinib clearli still key driver stock obvious sit
lot cash capit alloc prioriti mainli use cash
late stage develop asset ipf oa atop dermat
continu in-hous discoveri
galapago numer clinic program on-going would help us understand
ebb flow program move earlier later stage
chang impact line leverag spend given numer
on-going clinic program expect reach break-even
plan commerci asset think
spend build sale forc aspect commerci
restrictions/standstil agreement partner gilead
provid detail
vision compani go year
challeng face get plan manag
latest updat divis compani spin co
learn date work toward spin
see spin co gener sharehold valu time
independ co new overlap
manag team and/or board director two compani new
involv invest co
would make sens spin co first pursu partnership
talk pipelin asset manag new compani
abl develop product whatev way see best
lower growth prospect linzess recent return gout asset
bring sens urgenc potenti split compani
chang gi market put ad pressur price
linzess competit amitiza trulanc becom intens
investor surpris multi-year price adjust linzess
announc call would help us understand process
would abl comment lower growth prospect linzess chang
potenti commerci spend
would addit abdomin symptom claim introduct
chang outlook franchis
give confid linzess maintain ip protect given
outstand challeng patent
latest fda discuss regard phase program
gerd expect phase data initi commerci
expect product
praliciguat concern investor around safeti profil product
given one gi bleed seen phase provid detail
case give confid drug overal profil
relev data saw praliciguat diabet patient
hypertens move forward differ indic diabet
nephropathi hfpef respond investor view decis
discontinu develop diabet hypertens sign failur drug
olinciguat recent disclos posit data achalasia stop
develop indic pleas walk goal
studi chang complet studi would walk away
indic despit posit result
latest updat still activ develop
think busi develop prioriti work
toward split busi develop hold split
youv ceo littl month think
chang would chang plan keep
strategi commerci andexxa differ
place came board
help hospit come board start use andexxa
quicker biggest hurdl hospit adopt
sale andexxa better-than-expect around
confus magnitud stock vs pull-through could help us
understand level stock number patient actual treat
surpris initi usag andexxa primarili patient
intracrani hemorrhag expect see usag beyond ich
indic hospit re-ord
frequenc re-ord hospit primarili earli access
new technolog add-on payment help adopt would speak
work long
expect chang shipment method hospit wholesal
come market chang impact top-line
plan conduct post-market commit studi andexxa
would happen get complet time-frame discuss
fda
feedback receiv medic commun need
cardiologist vs hematologist vs
differ
think opportun andexxa surgic set either
urgent plan surgic procedur expect start studi
expect start studi andexxa surgic set would
neg fda decis impact time andexxa surgic set
discuss european regul andexxa progress compar
thing went us
clear key focu andexxa bevyxxa
long-term plan bevyxxa would consid divest partner
europ given regulatori setback plan potenti out-licens
bevyxxa europ expect stop develop
cerdulatinib explain develop strategi asset
expect spend came meaning help us think
push pull sg spend
also help us think gross margin beyond especi given
impact suppli sale
alxn presenc increment data investor see
confer
review strategi expect convers soliri patient
multipl life-cycl manag initi line could
perhap discuss co-pay dynam drug deliv
infus self-administ sc
price push-pul incentiv convers also
captur increment valu creat drug
investor think potenti price differenti across indic
expect earli ahu readout
reason expect volum growth per region soliri base
investor expect term price headwind go forward consid
happen brazil turkey notabl trend
investor awar order understand base busi evolv
come year
strensiq provid color around patient split term age
consid substanti price differ may see across group
soliri launch gmg continu make posit headway would abl
provid guidanc abl execut well indic
type progress expect next year
investor think ex-u gmg opportun soliri rel
expect signific headwind next coupl year consid
trial indic current on-going expect start next
month includ
strong launch mg recent posit data soliri nmo
partnership complement pharma could provid color emerg
neuro franchis term potenti indic explor al plan
also develop nmo
compar agent class
much interest asset driven first-mov statu waiha
recap biolog indic fcrn antagon could
particularli well-suit type data expect see next
year waiha
multipl agent current develop gmg see landscap
evolv time
recap intend modif trial
expect chang translat term potenti adopt price
dicerna partnership recent announc could outlin
interest target complement cascad could particularli amen
rnai approach
youv deliv financi ambit rais guidanc time
execut bd front reason expect continu
oper margin expans start conduct trial pipelin item
youv activ bd recent could outlin capit avail
new initi front would ideal profil tuck-in asset
consid multipl program clinic
outlin current unmet need gpp ppp target product
profil indic
outlin expect readout gpp bar
success trial read-through recent competitor updat gpp
agent also target pathway
underli rational explor ppp efficaci bar
clinic readout ppp
indic role well establish
etokimab differenti product clinic target
think evolv treatment landscap asthma atop
dermat key point differenti believ etokimab may
room multipl player
dupilumab approv asthma hybrid label eosinophil phenotyp
oral corticosteroid-depend asthma regardless phenotyp inform
develop strategi etokimab indic
recap evid support role chronic rhinosinus
nasal polyp crswnp market opportun indic
etokimab posit treatment paradigm
etrasimod recent outlin uc design initi
take execut propos timelin expect updat
regulatori front crohn program
provid updat trial enrol etrasimod pbc potenti
broadli think develop strategi etrasimod
earlier year indic possibl explor indic
autoimmun hepat dermatomyos polymyos sarcoidosi recent
outlin plan studi atop dermat outlin overal
criteria take indic clinic expect balanc new program
versu exist pipelin think potenti price differenti
olorinab fit within overal strategi could differenti
exist product intend indic
ralinepag updat metric investor expect progress
phase program
read-through posit outcom selexipag triton initi tripl
versu initi dual oral combin studi much readout impact
address market ralinepag
signific investor focu valrox hemophilia gene therapi
outlin fviii express level achiev clinic trial
level chang time risk go high much patient
variabl patient
make decis blind valrox trial reason
blind trial frequent patient studi evalu
plan disclosur futur data updat
walk strategi go two differ dose
outlin respect design two studi time enrol
complet long baselin run-in trial
expect relat long-term durabl fviii level drop littl bit
around week patient dose dose hypothesi
occur literatur publish support hypothesi
safeti profil valrox disclos lft
elev trial amend protocol walk
exactli observ protocol amend made
protocol amend
mention day one key gate step acceler
approv studi agreement fda assay use
measur fviii express walk us decid use
chromogen assay abl achiev fviii normal studi
use assay
indic might file acceler approv valrox walk
data packag would requir stand
perspect would exact process take interim data
would interim inform report control place would earli file
driven pre-specifi interim analysi
think potenti cost produc singl dose valrox
much manufactur capac today mani patient
outlin valrox commerci opportun launch forese certain
patient segment earlier adopt frame potenti price valrox
asset vosoritid achondroplasia outlin new data
present day week contextu
improv growth veloc mean patient
outlin mechan action pk profil drug
vosoritid differ clinic stage competitor achondroplasia
walk vosoritid safeti profil seen hypotens
discontinu rate studi
may fda host achondroplasia adcom meet provid
perspect meet degre confid chang growth
veloc approv endpoint
outlin market opportun vosoritid age growth plate
close percentag case sporad vs famili approach
compar therapi develop
recent announc pku gene therapi indic multipl
gene therapi earli develop outlin broader gene therapi
strategi indic pursu
provid updat regulatori path forward
product expect next updat program market
opportun asset
broadli speak margin expans strategi next
receiv question investor lt visibl revenu tail
exist baselin think go difficult replac
ert like vimzim aav lentivir gene therapi approach
percentag revenu come us vs ex-u sale much
exposur brazil turkey reimburs process
brazil turkey ex-us/eu countri price power
area price chang time
outlin ip portfolio exist product
provid updat palynziq launch mani patient drug
today mani expect drug end year
price palynziq much revenu receiv titrat phase
vs mainten phase outlin palynziq eu timelin
lead asset bempedo acid recent complet trial recent
result month outlin patient background drug
explor summar result result compar
outlin clinic meaning term ldl-c reduct
target ldl-c per treatment guidelin evolv time
provid hscrp improv well well valid hscrp
biomark degre improv see drug
outlin result achiev mace result
outlin saw term someth would like
get label hypothesi mechanist perspect
see benefit
safeti major area focu investor outlin saw
safeti perspect term ae sae rate discontinu
rate rate lft trial compar
signific investor focu death unrel treatment
provid detail natur death give confid
death spuriou discontinu rate studi
outlin design cvot trial compar previou cvot
trial result hand confid trial
outlin degre confid approv base ldl-c lower
ahead potenti cvot result see biggest question
signific investor focu go-to-market strategi perspect
potenti partnership ex-u outlin econom look
potenti partner provid updat statu partnership
indic desir commerci us alon least initi
outlin address patient popul specif patient segment plan
target first larg sale forc think need address
market time potenti scale-up think
outlin plan differenti therapi therapi
market develop expect out-of-pocket cost
bempedo acid compar
multipl asset develop variou compani
explain differenti competit
feedback physician patient far regard side effect
prime dose think on-target driven anemia manag
ae profil compar exist therapi
view futur market opportun therapi nhl
well indic comment approach versu
emerg treatment altern cell therapi
see highest unmet need commerci potenti among
indic current develop rank-ord
priorit
strateg view potenti partnership either commerci
think necessari random studi phase
could give color plan anti-sirpalpha antibodi program
non-oncolog indic think
outlin design solid tumor clinic trial type data
expect next year ovarian cancer number patient length
follow etc level respons rate would consid clinic meaning
popul
lead asset arikayc recent approv treatment ntm lung
diseas outlin ntm lung diseas contextu
diseas burden natur histori patient diseas prior
approv arikayc patient manag
outlin arikayc clinic data mean patient
import cultur convers clinician show term function
arikayc approv address see drug fit
treatment paradigm address market well diagnos
diseas preval diseas chang
march mobil team start educ clinician commun ntm
rais diseas awar tri emphas
clinician well receiv messag
outlin current treatment landscap ntm go-to-market
strategi central treatment ntm patient frequent
patient go doctor visit mani center target
target pulmonologist vs infecti diseas doctor common
question physician see differ comfort arikayc
base area specialti
outlin current commerci capabl term size sale
forc see size current sale forc suffici
continu add rep
describ impedi barrier encount expect
encount arikayc launch
one area investor focu arikayc reimburs outlin
mani patient cover medicare/medicaid process get
formulari base launch date significantli payer manag
arikayc use averag patient out-of-pocket cost
elev ae rate trial patient first commenc
arikayc strategi employ mean mitig observ
trial dysphonia black box warn etc physician
view box warn see ae perspect
consist clinic trial
walk physician patient train undertaken
outlin patient onboard process frequent clinician go
see patient clinic process place mitig risk
possibl drug discontinu
heard ntm at treatment guidelin may process
updat describ heard relat process
timelin guidelin may releas expect arikayc
incorpor guidelin impact expect
expect term durabl treatment patient cultur
convert patient cultur convert
respect arikayc launch outlin current manufactur
capabl abil suppli market
look one year today consid success
arikayc launch current guidanc arikayc sale level
confid achiev
time disclosur launch potenti metric
outlin post-approv requir plan
provid updat arikayc ntm front-lin set trial design
provid updat statu arikayc approv japan
gate step market opportun japan strategi ex-u
 plan commerci market find commerci partner
set plan explor arikayc mainten therapi
pathogen would design potenti mainten therapi
outlin current sg spend expect
spend chang come year
walk decis develop vivo ex vivo gene edit
capabl two platform complement outlin
strategi respect select therapeut target guid decis
move forward first attr vivo sickl cell ex vivo
outlin rang edit made use edit
easier make outlin indic address
kind edit
outlin way bodi repair dna break way get
cell favor one repair mechan anoth advantag
disadvantag non-homolog end join homolog direct repair
far away make complic edit gene insert
front outlin preclin gene insert data present
recent preclin present found blunt-forc gene insert
effect approach easi control degre express
compar contrast crispr gene edit system
explor outlin differenti rel gene
one area investor focu differ deliveri vehicl use
outlin advantag disadvantag use lipid nanoparticl vs aav
vivo gene edit platform lipid nanoparticl use target
tissu besid liver
outlin lipid nanoparticl degrad long
process take
outlin step take mitig potenti off-target effect
seen off-target effect preclin studi differ
approach evalu off-target effect
lead program ttr outlin observ preclin
studi efficaci perspect well valid ttr knockdown
relat function benefit degre ttr knockdown clinic
meaning mani month follow-up much variabl
respons see safeti signal
recent announc go optim ttr approach
outlin specif modif make drove decis
well valid preclin ttr model predict model
rel human
sever drug approv ttr space outlin market
opportun ttr valu proposit offer patient
two collabor agreement regeneron novarti
outlin agreement cover area exclus right
releas interest data suggest redos possibl given
abil think dose enter clinic
intent dose lower end therapeut rang redos need
multipl program develop frame time
catalyst program
sinc new technolog provid perspect term
mani year data fda want see approv gene edit therapi
main area focu regul
outlin ip posit recent receiv patent outlin
patent cover provid context around histor ip litig
occur
univers california
broad
investor close focus mavacamten treatment hcm
outlin hcm diseas burden treatment landscap certain mutat
associ sever phenotyp risk death hcm
walk us data obstruct hcm patient goal
studi abl show purpos cohort
mavacamten studi ohcm provid updat
enrol timelin explor ohcm trial outlin
design trial walk dose adjust process
studi decis dose adjust determin
explor ohcm trial outlin primari endpoint much
variabl see peak studi tri lower
risk placebo out-performance power trial expect
placebo respons rate mani patient achiev primari endpoint
compar patient baselin mavacamten ohcm expect
patient baselin explor patient baselin compar
averag hcm patient
recent present new mavacamten data aha walk us
data present
recent start mavacamten trial non-obstruct hcm provid
updat statu trial differ diseas burden
obstruct non-obstruct diseas
outlin design nohcm trial efficaci endpoint
see clinic meaning want see move
drug forward patient set time result studi
walk mavacamten commerci opportun
address market percentag patient obstruct diseas
see mavacamten fit treatment paradigm outlin
commerci respons rel sanofi respons
involv number outreach effort increas hcm diseas
awar diagnosi outlin effort undertaken
learn
describ perspect price confid price differenti
rel commonli use cardiovascular drug comp
consid
walk mechan action compar
explor dilat cardiomyopathi dcm walk
dilat cardiomyopathi diseas burden current treatment paradigm
area unmet need
recent disclos addit result studi healthi
volunt outlin saw studi safeti efficaci
perspect see arrhythmia give confid drug
activ benefit patient
studi design studi walk
see clinic meaning stroke volum eject fraction arrhythmia
outlin agent develop efficaci achiev
agent
base know date expect need titrat
patient think one dose could effect everyon
plan start studi outlin potenti design
trial endpoint potenti consid
outlin commerci opportun area differenti
see rel omecamtiv earli initi thought
potenti price see fit treatment paradigm
touch upon drug discoveri platform think separ
competitor recent announc sever addit program outlin
program time potenti updat
investor heavili focus linzagolix treatment endometriosi
uterin fibroid outlin mechan action differenti
strategi rel competitor burdensom patient physician
outlin design endometriosi trial mani patient
report data week
outlin linzagolix endometriosi clinic data
strategi dose outlin saw
primari endpoint overal pelvic pain see secondari endpoint
patient global impress chang result compar
elagolix orilissa relugolix
investor acut focus linzagolix safeti profil endometriosi
see term see respect hot flash
bone miner densiti chang chang bone miner densiti necessit
use add-back therapi
endometriosi see dose respons walk us
pelvic pain respond rate non-menstru pelvic pain respond rate
differ dose wk defin respond
endpoint compar explor competitor
endometriosi move forward key area focu upcom
meet fda later year outlin potenti design
trial expect design patient baselin differ
outlin view market opportun endometriosi
degre unmet need plan price product expect
patient pocket cost expect durat treatment
linzagolix also explor uterin fibroid current two trial
outlin pace enrol trial mani trial site
walk us data uterin fibroid give confid
trial
frame market opportun uterin fibroid current
treatment uterin fibroid outlin expect durat
treatment uterin fibroid patient
outlin ip landscap endometriosi specif ip portfolio
walk us nolasiban clinic data implant think
saw greater efficaci rel placebo follow day embryo transfer vs day
outlin design nolasiban implant clinic trial
design trial compar implant power implant
outlin regulatori strategi nolasiban key gate step
fda
outlin commerci opportun nolasiban ivf
reimburs process walk us pharmacoeconom argument
nolasiban
plan cohort data outlin
look see efficaci perspect outlin potenti market
opportun product
signific investor focu risdiplam firefish sunfish sma trial
provid updat time enrol complet firefish
sma type part pivot studi walk us time potenti data
releas firefish part type sunfish part type sma trial
recent present updat result firefish part walk us
data releas put result context natur histori
outlin potenti differenti spinraza result compar
spinraza type sma result
need show firefish pivot part studi success
compar expect baselin part pivot studi rel part studi
also present risdiplam sunfish part result type sma
outlin result achiev compar result spinraza
compar baselin characterist sunfish part studi spinraza
cherish studi think about/interpret result sunfish part
enrol older patient cherish differ hfmse
outlin sunfish part efficaci age group see greater benefit
patient treat earli separ walk efficaci type
set vs type set
outlin risdiplam safety/toler seen ocular issu
patient discontinu trial
plan provid updat sunfish firefish part studi
potenti time updat
outlin design sunfish part pivot studi power
studi need show pivot trial success
expect term placebo perform
also third risdiplam trial jewelfish outlin purpos
trial time potenti updat
outlin market opportun risdiplam econom
program see risdiplam fit evolv sma treatment landscap
emflaza approv treatment dmd exclus us
provid updat emflaza sale see term
complianc patient uptak degre payer pushback see
percentag us market emflaza vs prednison
translarna approv ex-u treatment ambulatori nonsens mutat
dmd patient provid overview reimburs process eu
frequenc renew provid updat statu
outlin revenu growth rate next year outlin
growth driver translarna
comment potenti read-through sma/risdiplam gene
describ broader platform strategi indic interest
pursu platform capabl
recent acquir aadc gene therapi outlin clinic data
program gate step potenti approv file
market opportun aadc
walk us time ind file freidreich ataxia
construct design rational approach view clinic
outlin gmg trial design compar recent trial
indic enrol criteria clinic endpoint etc
efficaci expect gmg trial
sever agent current develop gmg expect
landscap evolv zilucoplan fit treatment paradigm
outlin potenti price strategi gmg may compar
exist therapi plex/ivig soliri think potenti price
go current program pnh favor dataset
would look like zilucoplan indic competit expect
enrol nave switch patient
zilucoplan potenti commerci posit pnh
given multitud complement-medi diseas tell us
indic plan develop zilucoplan
investor expect see updat extend releas version
zilucoplan oral complement inhibitor product candid
signific focu dmd gene therapi outlin
clinic data recent publish compar result
observ natur histori put perspect function result
shown rel age-match popul
speak variabl dystrophin express patient rel
first patient anyth uniqu particular patient
investor focus ck level comment
variabl ck time patient frame earli data within
context outlin averag ck level patient becker
muscular dystrophi level compar patient dmd
octob updat mention patient requir increas steroid
address ggt elev outlin protocol regard steroid increas
long patient higher dose steroid patient steroid dose
return baselin
mention meet soon fda discuss potenti
registr path dmd gene therapi provid detail key area
focu meet frequent abl speak fda
one goal upcom fda meet discuss potenti design
outlin current thought process trial design thought
primari endpoint trial discuss think
reduc risk placebo out-performance outlin patient
popul plan enrol studi strategi address older
younger patient
provid perspect think potenti durabl dmd
gene therapi much durabl observ preclin studi
outlin patient popul plan enrol studi
strategi address older younger patient potenti endpoint would
explor popul
dose level explor preclin tox studi seen
immun respons either preclin clinic capsid enzym
manufactur major focu investor outlin current
manufactur capabl time commerci scale-up process
patient pivot trial dose commerci scale materi
beyond dmd expect lgmd result
look see provid initi data soon expect could
see clinic benefit much leverag experi dmd give
give confid program
walk us natur histori lgmd much variabl
diseas progress patient predict biomark
broadli lot literatur publish lgmd outlin
step undertak help better understand diseas burden
think pursu four lgmd subtyp
walk market opportun lgmd diseas
preval timelin bring lgmd program clinic
less discuss multipl catalyst horizon exon skip
therapi outlin upcom catalyst variou program
provid updat exondi uptak us percentag exon
amen patient drug outlin ex-u strategi exondi
outlin design exondi confirmatori trial time
level exon skip achiev mdx model pmo rel
ppmo degre heart penetr ppmo rel pmo
outlin ppmo/ safeti profil preclin model model
much follow look present data
provid clariti gate step prior move
sanfilippo pivot trial outlin differ therapi
rel
recent in-licens gene therapi mp provid clariti
gate step prior move sanfilippo pivot trial
outlin differ therapi rel
outlin learn clinic studi believ four patient
plan incorpor pivot trial
mention plan bring cmt gene therapi program clinic
base seen preclin quickli expect show
fda recent issu gene therapi guidanc outlin well align
guidanc strategi
walk us broader strategi compani team done
lot bd past month build pipelin view addit
lead program dmd gene therapi outlin design
construct promot capsid use walk design
micro-dystrophin nno region import design
compar competitor
walk saw preclin studi dmd gene
therapi program anim model explor dystrophin express
level abl achiev variou anim model dose
dystrophin express across differ target tissu cardiac vs
skelet muscl addit percentag dystrophin posit fiber
predict anim model dmd aspect good translat
move clinic
outlin preclin toxicolog work perform dose
level explor
outlin design studi time dose
patient dose plan explor statu studi
commenc redos patient quickli move higher
dose level need
compar clinic trial design rel competitor
walk natur safeti find first patient dose
think caus safeti issu base safeti find
clinic trial strategy/design chang soon plan start dose non-
ambulatori patient
expect first data updat time point collect
biopsi muscl biopsi walk
biopsi process much inher variabl measur dystrophin
express function endpoint monitor
compar ambul non-ambul patient
meaning ck level much natur variabl
steroid protocol trial signific impact chang
steroid patient function result
expect durabl treatment much durabl
preclin model turnov rate cardiac tissu skelet
outlin manufactur capabl herp viru system
differ gene therapi manufactur approach advantag
disadvantag approach
manufactur major focu fda manufactur capabl
current place quickli expect scale process
outlin clinic develop regulatori strategi much
durabl data think fda want see prior approv
walk market opportun see area clinic
differenti rel competitor endpoint forese could
potenti evid differ think potenti price
updat provid
outlin biolog behind prophi steroid cours expect add
dose new patient certain curtail immun respons
without impact express
weve seen updat two patient treat competitor hem program
prophi steroid regimen administ pre-specifi window post-dos
much read-through/valid think data approach spk-
outlin detail rel construct mechan
action target inhibitor patient
compar contrast approach pomp gene therapi
program clinic
data present demonstr glycogen lower brain
mice recap involv diseas patholog
preclin find may translat human
given number center train administ luxturna
on-going patient identif initi reason pace launch
outlin expect next updat choroideremia program
would consid win dataset
youv report million cash equival
mention suffici fund need clinic program
includ guidanc expect ind besid
frame initi crysvita launch track rel initi
expect expect next month metric
provid investor go forward eventu disclos total crysvita sale
proport clinic trial patient convert commerci
breakdown adult pediatr
new patient start form trend indic high interest adult patient crysvita
estim proport address adult patient could deriv
benefit therapi
consid possibl regulatori submiss lc-faod could
provid insight potenti price comp address popul
current well-manag soc metric could help investor
understand commerci opportun
given broad sever spectrum seen over-the-counter could outlin
patient segment potenti address popul like
quickli move clinic explor pediatr patient
addit factor might take account
liver-direct gene therapi pediatr patient
requir work dose escal level cohort
requir addit insight saw respons pattern
cohort
expect cohort readout efficaci
endpoint go provid could frame would clinic
meaning improv metric
follow present plan build investor confid
stori
latest progress phase trial plan expand
tumor beyond nsclc rcc
expect addit announc trial term
expans arm
think may abl start registr trial
resistant/refractori patient either renal lung cancer
see path forward front-lin therapi indic
bind affin beyond consid adenosin
receptor beyond etc preval throughout bodi
addit biomark data share highlight impact
patient
theoret safeti issu come receptor
think compound differenti other also move
antagonist mab clinic nv azn
dose schedul
talk theoret advantag differenti target
oppos could combinatori potenti product
thought combin beyond either i-o
plan itk inhibitor bring clinic next
year potenti see compound possibl road
block could encount
focu recent struggl uk busi labor
side take minut explain go uk labor market
caus issu much relat brexit uncertainti around
immigr statu worker outsid uk brexit transit
occur much help
expect see wage pressur due recent salari increas announc
nh occur sever year nh commun
whether would increas reimburs rate off-set wage pressur
much nh pay rel much independ provid pay
signific differ employe benefit
expens agenc nurs rel employ nurs
consid purchas start staf compani
think could way help reliev labor pressur
saw labor issu intensifi coupl quarter look like
agenc labor spend might come margin exactli happen
differ prior quarter long expect current
condit persist
recent disclos regulatori issu relat comprehens
treatment center fals claim act laboratori servic provid
color issu mani across us total
give us sens total compani revenu exposur busi line
similar issu past
talk open entertain sale uk busi
compon recent earn call indic
review uk portfolio look specif whether divest
close under-perform facil would still consid sell whole uk
busi much progress made look under-perform uk
facil whether action taken subset uk facil
updat potenti sell nurs home busi uk
facil said referr stream halt
period time earlier two facil
far along facil build back censu referr
stream complet back normal slowdown addit
color around strong us ss revenu growth report
materi improv jv/de novo facil
newer facil roll same-stor calcul think ss growth
rang could continu move forward expect fall back
uk ss revenu growth look good year averag ytd
think averag around ss growth uk sustain long-term
back discuss censu weak uk believ
relat transit uk shift around respons
local author put local level sustain
transform partnership pretti much work way
implement process see stabil still
transit mode caus slowdown flow patient still point
length stay us continu see modest pressur report
metric get updat would still say pure relat busi
mix chang see actual lo pressur within particular busi
line see lo pressur particular payor class
talk two acquisit announc recent long
look pipelin
continu consid
look like acut psych hospit part health system
includ servic post-acut orient right
forese benefit psych hospit align health
focu still acut psych hospit term acquisit interest
continu expand ctc footprint well residenti facil
still larger deal could look near futur
guidanc seem pessimist impli revenu growth
meaning declin ebitda ep get earli read
guidanc assum labor situat
bad
competit environ like uk pe firm other make
signific invest behavior healthcar uk today
pace bed offload nh like today slow
long pipelin new opportun want give
report earn announc renew kaiser msp
sever year signific given kaiser largest custom
provid color chang new contract vs old contract
could provid opportun move forward
provid sens extent respons
kaiser staf need across geograph area
portion kaiser facil
percentag revenu come msp increas significantli
recent year describ msp work differ
tradit staf relationship valu proposit offer
penetr msp healthcar staf today still lot runway
new msp think futur win come take share
anyth uniqu certain hospit make less like want
msp relationship msp common smaller larger hospit
averag size msp contract today see growth
busi particularli larger smaller contract
averag term msp contract long take ramp
msp contract ramp period reach fulli
asid msp see greatest opportun outsid
direct fill rate today msp non-msp client
although higher fill rate mean higher revenu lower fill rate provid
stabil fall demand staf servic target fill rate
balanc factor gener tri push fill rate high
key constraint abil increas fill rate
simpli abil recruit clinician certain geograph
area might msp provid dont
presenc success fill posit
much variat across msp amount job fill directli
fill other fill seem obviou
ramp msp would lower fill rate main characterist
drive differ fill rate across differ msp
think locum msp today see much growth
overal opportun look like
updat us progress locum tenen segment system
implement come along expect show growth segment
see gradual acceler growth time point
think see step chang growth
updat us think normal organ growth level
across three segment
drill specif area within
segment fastest grower weakest grower even
declin point
see declin premium rate mix pretti much level
point expect turn around y/i basi
longer distort metric
past year discuss pullback demand
custom recent quarter seem like improv
somewhat updat us see client still
state pull-back see chang rel trend call
past respect client increas perman hire increas overtim
trend stay consist specif client
see neg impact continu shift lower cost outpati
set rather inpati set target initi ensur
staf provid choic outpati set well
current presenc offer outpati set today
particular nurs specialti crna psychiatr nurs etc
see higher demand right need particular need
particularli difficult fill
geograph area challeng right
challeng recruit right level recruit
stabl tri increas level structur compens
recruit fix vs variabl differ healthcar staf firm
make chang compens structur attract
price trend recent bill/pay spread stabl see
pressur see pressur pay much flexibl
increas price
state right healthcar staf industri
gener major acquisit prioriti
trend see wage inflat
discuss see term expens healthcar cost
busi execut search perform
compani recent report result said quarterli confer call
felt could growth ep high singl digit/low doubl digit rate
impli consensu low rate growth gail
mention sever time long-term target question
first long-term perspect talk driver allow anthem
obtain level growth whether organ growth across key busi line
specif key headwind tailwind
consid think next year
item mention other medicar advantag
growth health marketplac exchang profit growth compani specif
manag respons restructur specialti servic cross sell
biggest opportunities/challeng see ahead
market perspect specif
obvious result last week elect polit landscap washington
set shift bit januari shift seem good one fine
current statu quo healthcar polici perspect sens
mco ok mco push major legisl initi
healthcar gener happi way thing go
way think polici backdrop head next year
put take govern segment
respect compani said expect individu medicar advantag
enrol grow mid-double-digit rang stabl margin estim
could result tailwind next year depend land
pre-tax margin rang believ youv said middl target
margin rang
enjoy benefit improv bonu payment vs
roughli live plan vs factor
think margin enrol growth
antm rate came last month show roughli percentag
point declin particip understand roughli percentag point
percentag point declin antm rate driven compani
contract ohio anoth six percentag point declin driven
contract ny better sens point drove drop
book action compani take off-set potenti
headwind
recent posit group opportun remain
untap compani especi given strong commerci aso busi
compani expect total membership exceed discuss
driver also share thought opportun
busi long-term
provid updat antm partnership cross minnesota
serv medicaid dual elig member look similar
partnership blue state
talk bln worth increment busi opportun
medicaid end provid updat
new busi opportun includ potenti medicaid
re-procur antm exist contract
understand california may begin reprocur process next year
signific medicaid opportun ca reprocur offer
potenti increment busi larg effort maintain statu quo
believ texa star plu program account roughli bln antm
revenu tx whole repres bln revenu
updat reprocur
 util trend expect
anthem result benefit better expect local medic cost trend
compani bia local medic cost trend
mid-point rang discuss driver
trend favor rel forecast number year
impact discuss larg employ regard price year
ahead pushback among corpor client regard industri price
toward cost trend seem beat everi year
third quarter highlight higher cost trend medicaid primarili due
unfavor impact period adjust elabor
assum true-up state level everi year everi quarter
made want highlight item
individu busi pressur number year
bright spot mco compani highlight
margin book come high end rang
happen exchange/individu market price final gotten
accept level extent driven fact peopl
histor abl get coverag coverag sever
year issu relat pent-up demand play point
along line compani said assum return normal
exchang margin next year preliminari comment outlook
driven return increment competitor individu market next
year simpli rate price increas segment moder
grow specialti program membership prioriti
last year half progress initi much
runway think long-term compani said would like close
profit gap aso member fully-insur member
progress goal target could
continu expect new pbm deliv least billion gross
pharmaceut save run-rat basi januari think
next year larg year prepar roll-out
mileston watch activ ingeniorx
sell season next year launch
balanc sheet capit deploy
think capit avail end
d/c ratio roughli bln cash cash equival
invest parent compani remind us compani lt d/c
target
given compani focu get pbm set-up next year
larg scale transact tabl
movement insur forward integr least
provid space urgent care clinic doctor group surgeri center anthem
purchas doctor group florida medicar advantag acquisit
caremor subsidiari talk step take
build provid specialti platform
msp seem nice sourc growth recent year describ
msp work differ tradit staf relationship
valu proposit offer msp
penetr msp healthcar staf today still lot runway
new msp think futur win come take share
anyth uniqu certain hospit make less like want
msp relationship msp common smaller larger hospit
averag size msp contract today see growth
busi particularli larger smaller contract
averag term msp contract long take ramp
msp contract ramp period reach fulli
asid msp see greatest opportun outsid
direct fill rate today msp non-msp client
although higher fill rate mean higher revenu lower fill rate provid
stabil fall demand staf servic target fill rate
balanc factor gener tri push fill rate high
key constraint abil increas fill rate simpli
abil recruit clinician certain geograph area might
msp provid dont presenc success fill posit
much variat across msp amount job fill directli
fill other fill seem obviou
ramp msp would lower fill rate main characterist
drive differ fill rate across differ msp
think locum msp today see much growth
overal opportun look like
updat us progress locum tenen segment plan
turn segment toward growth
updat us progress cost save initi exclud
initi see margin pressur cost save initi simpli
off-set view cost save initi actual improv report
margin somewhat stagnant declin recent lay
path achiev margin growth
updat us think normal organ growth level
across three segment
drill specif area within segment
fastest grower weakest grower even declin point
advantag rn perform thu far see start fill
msp see gross margin improv much
go
updat ceo search process anticip take march
mr grubb contract end date think resolut sooner
provid addit color resign presid workforc
solut fulli decis mutual agreement part way
plan leadership busi
see declin premium rate mix pretti much level
point expect turn around y/i basi
longer distort metric
past year discuss pullback demand
custom recent quarter seem like improv
somewhat updat us see client still
state pull-back see chang rel trend call
past respect client increas perman hire increas overtim
trend stay consist specif client
see neg impact continu shift lower cost outpati
set rather inpati set target initi ensur
staf provid choic outpati set well
current presenc offer outpati set today
particular nurs specialti crna psychiatr nurs etc
see higher demand right need particular need
particularli difficult fill
geograph area challeng right
challeng recruit right level recruit
stabl tri increas level structur compens
recruit fix vs variabl differ healthcar staf firm
make chang compens structur attract
price trend recent bill/pay spread stabl see
pressur see pressur pay much flexibl
increas price
state right healthcar staf industri
gener major acquisit prioriti
trend see wage inflat
discuss see term expens healthcar cost
highlight call two headwind mln unusu after-tax
profit commerci individu busi ytd pyd roughli
mln compani assum year-ahead outlook tailwind
highlight includ growth expans relationship
specialti product continu growth intern group disabl
life busi also flag mln tax hif relat tailwind
fair say base ep ci stand-alon
respect mln hif relat tailwind relat time issu
intra-year commerci renew contract attribut medicar
revenu ytd almost howev full year compani
guid approxim y/i growth would impli signific moder
y/i growth vs seen first three quarter
talk driver
let follow-up question medic cost trend outlook medic cost
trend outlook improv bp rang vs
compani start year initi outlook much bp
improv versu origin outlook would attribut broader favor
util trend much would attribut initi care
respect commerci individu busi hix live
off-exchang compliant live off-exchang non- live
end said call busi repres roughli bln
revenu would impli pmpm excess think
right addit confirm see stabl pre-tax margin
busi mid-singl digit rang believ like underli
assumpt also note normal individu busi
repres y/i headwind mln tax impli current pre-tax
margin book high singl low doubl digit rang get math right
said call expect hix enrol declin market
get competit confirm continu particip hix seven state
get right expect revenu book declin given
hix headwind mln seem must assum signific hix margin
deterior y/i drive
let follow-up medicar advantag relat question bid
public think enrol growth margin expect
next year view project enrol
growth compani said call goal grow revenu
high singl digit rang price closer shouldnt
expect exceed goal
peer talk group signific untap
opportun given strong commerci aso busi share updat
thought busi given strong commerci busi
call highlight outstand client retent level nation account
busi potenti win see growth market
histor describ market declin market market
share stabl longer case
talk result expans specialti relationship
commerci busi expect expans continu
elabor refer dental vision product
current penetr product among larg client
cigna group disabl life busi net margin thu far
think busi oper stabl margin level see
potenti margin expans opportun
note releas segment benefit expans
custom relationship continu innov product design distribut
strategi elabor
capit structur deploy
exclud esrx merger relat debt proce end third quarter
parent compani cash billion consid sourc use
parent compani cash exclud debt issuanc proce
expect capit avail deploy approxim billion
compani plan use cash hand increment cash flow de-lev
upper d/c ratio level roughli level post deal closur
impli compani might return share buy-back mode next
month share buy-back still achiev de-lever target
approv doj state remain six state
still go major one list state schedul hear
done public hear merger
plan formal issu outlook close esrx deal
plan wait earn releas guy decid
plan segment earn report pro-forma compani one
addit segment exist three segment david mention health
servic busi call
first offer accret estim esrx discuss
percentag addit result significantli outperform base
earn estim year assum whatev percentag
yield first quarter number use chang
expect light strong perform esrx line result
think initi comment double-digit accret year one close rel
ep estim roughli exclud share repurchas
final updat statu antm-ci litig well antm-esrx
non-recur item
begin let flush three non-recur item highlight releas
prior year ca ihss program reconcili expens relat conclus
veteran affair contract contribut charit foundat seem none
assum prior outlook first cost
reconcili relat california medicaid in-hom support servic ihss
program end decemb result estim pre-tax benefit
million note releas reconcili
expect final earli final reconcili follow
guidanc assum addit benefit possibl
neg true-up futur quarter
second respect conclus cnc contract depart
veteran affair patient-cent commun veteran choic
program compani incur million negoti settlement
sever cost note releas continu provid close
transit servic first tell us big contract
respect revenu member would bulk revenu
membership move cnc result addit expect one-
time cost relat transit futur
final compani record pre-tax expens million associ
contribut commit charit foundat relat fide
chariti cnc charit organ remind us contribut
discret cnc board timet predetermin commit
investor day talk roughli mln bln ca pass
payment roughli mln realiz
expect anoth mln doesnt seem happen quarter
color
cnc servic revenu declin sequenti mln expect
servic pick-up sequenti fide busi come board
much contribut fide servic revenu
mlr medic trend
cnc around bp higher consensu exclud benefit
ca ihss program reconcili benefit compani confirm call ca
ihss program reconcili benefit mln help
bp origin guidanc simpl math would suggest bp
posit impact full year origin guidanc howev compani
lower high end bp maintain low end would
essenti impli apples-to-appl basi actual increas
outlook full year think right ye would driver
particular busi trend unfavor
prior expect much return hif impact y/i
cnc note cost servic ratio neg impact
approxim basi point cost associ veteran affair
contract expir mean mln veteran affair contract
termin impact roughli mln cost servic remain mln
 expens
respect sequenti chang dcp flag four day impact
fide acquir fide roughli bln quarterli
revenu fide reserv bln four day increas dcp assum
fide busi would impli reserv relat fide busi
end increas mln get math right
conserv respect fide claim accrual process
concern need boost reserv compli cnc reserv practic
elabor time claim payment busi expans
two day impact dcp
seem long-term still expect dcp moder impli
headwind dcp revers move forward
note call one reason mco bid
north carolina medicaid busi could attribut complic natur
rfp specif manag care requir network mix
provid etc think stipul limit margin opportun
associ contract mco
tx reissu chip rfp respons due mid-
novemb expect award come project
start date star plu chip rfp
make nois state respect
procur process way contract award past
way background respons request tx offic governor
state auditor offic conduct audit evalu tool use tx hhsc
auditor identifi error evalu perform procur
test estim award valu billion procur
award and/or consid award januari march
five procur estim valu billion auditor
identifi signific evalu score error miss document
separ pennsylvania complet go shelv re-procur
tanf contract impact hix particip
reiter revenu commentari visibl revenu excess
billion also note current ep consensu y/i growth
guidanc mid-pint would within compani guidanc
rang compani provid addit detail investor day
decemb said look stabl enrol steadi margin trend
expect hix busi versu think right
local region competitor market expand re-
enter expect margin pressur membership churn
market off-set gain new market counti expand
footprint six exist market next year ga ks mo tx enter four
new state pa nc sc tn
risk adjust payabl mln end fair say
like assum roughli favor true-up benefit risk
adjust program accrual similar approach compani head
talk medicar advantag posit kind
growth see busi think call margin
busi matur level profit expect
margin improv vs
let follow-up tax rate quarter adjust acquisit relat
expens amort expens combin mln pre-tax adjust
mln tax adjust estim tax rate around hif
believ compani tax rate expect like mid clarifi
drove benefit quarter tax benefit beyond
impact item highlight page press releas
incur busi expans cost
compani rais busi expans outlook
impli busi expans cost
primari driver sequenti pick
cnc invest incom mln vs mln year ago good
quarterli run-rat move forward non-recur item line item
quarter
mln pre-tax acquisit relat expens compani flag
mln includ expens minor differ
remain mln acquisit relat expens includ
seri articl come ohio regard cnc envolv
platform deal ohio medicaid program ohio medicaid
spokesman said depart take cnc practic consider
reissu managed-car contract start call today michael
made comment regard fix cost per script program note
redact previou statement regard duplic function
wonder action remedi state gone make
sure placement rfp secur
complet equiti method invest rxadvanc rxa
full-servic pharmaci benefit manag pbm septemb made
addit invest rxa form convert prefer stock
earn busi equiti earn affili includ servic
midterm elect behind us thought regard congress
effort relat healthcar reform potenti posit neg
aspect democrat control hous gop senat perspect
restructur reposit compani acut care portfolio prioriti
last two year statu cyh divestitur program thu
far close plan close hospit hospit
origin includ divestitur program couldnt find buyer
decis make process around divestitur anticip
addit current unannounc divestitur remaind
much revenues/proce connect hospit
sold thu far pend definit agreement identifi
mani hospit divestitur program
right run-rat think come divestitur
use revenu base remov bln divestitur contribut
bln divestitur contribut mln three close hospit
get us roughli bln annual rev sound right
ebitda adjust roughli mln drag hurrican mln
drag divest hospit assum margin contribut
divestitur assum break-even result three close hospit
adjust stock-bas comp mln get roughli bln
ebitda margin seem right
margin profil overal financi perform differ cyh
statewide/region network local hospit market individu hospit in-market
competit individu hospit market competit
particularli focus segment divestitur plan
updat us situat lutheran fort wayn
continu issu busi usual point believ former ceo
lutheran attempt partner iu creat sever primari care
offic imag clinic inpati surgeri center urgent care center
remind us much revenu ebitda contribut
estim lutheran repres bln revenu
ebitda margin roughli
see labor front wage turnov product etc
comment competit physician find still
consider interest employ hospit effort simpli
recruit doctor refer physician staff
hear lot rise consumer healthcar fuel part
prolifer high deduct health plan impact
respond trend
discuss initi focus term
increas product oper effici much target benefit
alreadi achiev much yet go target
portfolio restructur program distract manag attent away
normal oper oper improv benefici
oper improv perspect divestitur behind
discuss capital-expenditure outlook next year remind us
key area capit deploy year next year capital-expenditure
chang time
think trend rural market continu under-perform trend
urban market economi driven payor driven natur servic
provid someth els
cyh first lien net debt ebitda leverag ratio end
believ start limit move implic
breach coven
solid price talk driver
compani benefit transfer center develop case mix trend
quarter
discuss ss admit adjust admit ebitda margin
pro-forma footprint rel current footprint
impact hurrican florenc sc nc
facil direct hit fl relat hurrican michael storm
path al ga sc facil quantifi impact
hurrican one wors
think rebas estim divestitur drag
ebitda mln mln high-tech see
benefit procedur move last year due hurrican much
ebitda contribut receiv hospit sold
thu far compani experi benefit relat flu
believ acceler ed visit off-set drop elect
ed case move part think
stand safeway partnership mani store
current partner current plan expans
also youv talk expand type basic healthcar servic
provid wal-mart locat updat us well
possibl would partner addit compani part retail
initi limit safeway forese futur
updat us revenu cycl manag partnership optum
see much progress point still front
light recent contract announc aet speak
differenti main nation lab peer also particip
dual-pref relationship would doctor prefer send patient
oppos anoth lab prefer relationship
obvious compani peopl talk physician get commit
there level visibl confid abil
estim volum benefit compani natur need
conserv give guidanc due lack visibl much volum
come way well much aet volum go away
ultim understand benefit gain outweigh
lose aet term time reason think could lose
expect aetna volum faster rate gain expect unit
addit color commentari around recent announc in-network
relationship horizon cross new jersey start
opportun point futur get medicaid member within
horizon well
compani previous mention volum could flip quest
bit earlier prior start date in-network arrang
see point
talk profession lab servic pl servic hospit inpati
lab differ pl option tier
signific pl relationship right pipelin
look like see acceler discuss hospit
relationship denver market progress
receiv posit feedback hospit think there still
opportun expans partnership
know work opportun around data monet
potenti work other pharma compani
updat area signific type opportun well-
posit think marketplac vs competitor particular vs
labcorp in-hous cro
final rule physician fee schedul said mani outreach lab would
begin report next cycl clf would impact rate
also chang calcul medicar revenu way could make
lab need report data well much win quest
lab industri industri continu advoc addit chang
revolv around tri get relief clf rate prior
regard pama see increment pressur commerci insur
use clf price refer point abl fight back
pretti effect
lay path maintain margin next coupl year
pama impact increas
expect signific market share shift due pama think
mostli come independ lab market share vs labcorp vs
independ lab trend recent year expect trend
next year materi differ last year
 pipelin look like right see
import opportun pursu
see increas pace deal progress increas potenti
deal given pama primarili hospit outreach lab space
see independ lab well
accept valuat potenti target fall pama take effect
recent announc acquisit provant health hooper holm
provid health well-being servic employ support health care cost
manag flesh busi fit quest
along optum other announc earlier year would
launch pilot program use blockchain technolog improv data qualiti reduc
administr cost describ program updat pilot
program run signific way still sort plan
updat us headwind around prescript drug monitor vitamin
hepat headwind much progress make improv
area possibl
asid three area call last quarter issu
crop industry-wid perspect would dampen organ
revenu per requisit decreas y/i first two
quarter year anyth materi differ go third quarter
function comp prior year
think total amount tax reform invest spend
youv spent somewher around mln first three quarter
well expect mln much think end spend
never spent get push
midpoint previou revenu guidanc prior report
consensu revenu growth around call compani
seem emphas long-term outlook call revenu growth compound-annual-growth-rate
oppos particular year well point would least
revenu growth obvious consensu revenu number go
come rebas lower guidanc interpret
comment talk revenu growth rate well
mix congress see dc landscap evolv
volum price trend
compani said long run adjust admiss like
facil basi oper fast grow urban market across
countri target assum properti experi volum growth
similar underli market trend factor would allow
outperform object
volum help compani focu ad access point
freestand er health clinic outpati surgeri center etc
judg success invest tri extend reach
compani look non-urban set smaller commun market
hca manag medicar admit grew facil basi
repres total medicar admiss remind us whether shift
tailwind view relat revenu per admiss medicar term
profit medicar
ss manag care admit adjust admit increas respect
best trend sinc function easi comp quarter
see acceler commerci volum trend facil self-pay chariti
admit increas repres total admit last year
strong economi think see mitig
term er visit compani saw declin low intens visit
level rise high acuiti level trend go
time would think point wed see low intens
visit move move think approach point
ss urgent care visit y/i consolid basi
think drive declin ss basi birth two posit
quarter neonat admit declin y/i wors trend sinc
color two trend
hear lot rise consumer healthcar fuel part
prolifer high deduct health plan impact
respond trend
see term shift valu base payment extent
qualiti becom compon reimburs structur either commerci
govern payer see qualiti becom greater differenti factor
among competitor futur
labor cost number good quarter ss swb run
rev vs last year also salari per equival admiss
strong y/i increas wage still run rang head
also respect use contract labor describ
significantli y/i simpli function put focu
facil manag level someth els
comment competit physician find still
consider interest employ hospit effort simpli
recruit doctor refer physician staff
comment suppli expens trend see increment
success area healthtrust hpg success get
healthcar system umbrella discuss opportun
see hpg opportun signific way market hpg
acquisit divestitur
still expect deal close past month break-even
end reason ebitda target hospit specif
updat savannah
balanc sheet capit deploy
net debt ebitda declin end third quarter compar
end seem toward lower half compani
target rang see move back closer would
drive higher
said earn call would increment capit come
line next year compar year project compani
undertaken last year sound like think tailwind
invest creat consid similar tailwind capit creat
year relat volum growth right
note earn call expect ebitda growth look similar
ebitda growth roughli mid-point outlook assum
hit roughli ebitda margin acquir hospit would impli roughli
mln y/i ebitda benefit around fair say compani lt
ebitda growth outlook still addit tailwind acquisit
give higher visibl close ebitda growth
quantifi increment y/i dsh benefit goe effect
compani said call see medicar ipp rate updat
vs recent past
understand way earli talk howev acquir hospit
still runway term margin improv fair
say compani good ebitda growth visibl like come
favor lt growth outlook
talk outlook emphas sever time mission
acquisit includ earli commentari next year understand
mission rel profit system right would fair
assum mission deal complet would addit ebitda even
ep almost immedi ahd say system gener roughli bln
annual rev mln ebitda margin
provid brief overview busi model valu proposit
custom choos busi
custom altern busi
dont larg scale direct competitor smaller market
competitor
compani provid similar outsourc servic stadium
hospit particular reason compani would tri enter
snf dining/nutrit housekeep market compet one
compani tri compet would advantag
talk current gross margin target path/vis toward
achiev
youv discuss expand gross margin time hit run
rate particular timelin expans
need reach level
still expect dietari margin reach similar level housekeep margin
time long think could take would someth like two
year like five year
talk recent custom restructur contract
situat custom might consid
rational behind provid limit servic custom
anyth de-risk certain financi challeng
custom unwil agre appropri contract term
fulli initi custom ask chang
talk dso trend recent particularli follow charge-off
took earli year
updat us progress replenish manag pipelin
back normal specif region progress
slower other
flow strong third quarter solid ytd get
point your consist hit good cash flow number would consid
substanti increas dividend think would
special dividend share
one-tim cash distribut
see top-lin growth trend across two busi line long-
talk plan expand busi alf senior live
facil mention past thought movement
toward would meaning competitor area
budget new busi busi ad last
year get budget
updat strength overal custom base issu impact
patient-driven payment model snf industri
reit snf oper optimist benefit
demograph shift come futur year say could
see benefit earli view
note call expect grow ep excess
baselin ep fact compani see guidanc mid-point
rang consensu would impli mid-point reflect growth
excess y/i remind us headwind tailwind see
versu earn growth assumpt reflect increment share
buy-back y/i stabl pyd
discuss around ep growth earn call
clarifi compani messag impli even hif return
compani enough lever pull grow ep lt target rang
also would hinder progress term get individu pre-tax
margin
expect individu enrol increas live
repres y/i growth compani expect add
live repres y/i growth given compani
improv y/i benefit expand new counti market introduc new
product enhanc relationship broker two rate plan
key market wonder expect growth much higher
would call good conserv start point given oep
still go
one uncertainti highlight call return oep
first time sinc oep would run jan march allow
member make singl switch plan return origin medicar
remind us kind attrit industri use see oep place
prior
reiter call individu margin like fall short
lt target still improv y/i understand dont want
disclos pre-tax margin individu busi say
much return hif averag flu activ drag
pre-tax margin least two item turn favor
expect group live grow versu addit
peer talk posit trend group busi
updat thought busi
medicar pdp membership expect declin live
live driver see busi turn
around respect enrol
group specialti segment
maintain group medic cost trend outlook highlight
bia toward lower half trend book similar retail segment better
inpati pharmaci partial off-set higher outpati
expect group specialti earn nice pre-tax growth
would off-set lower tricar profit given posit final
settlement receiv associ previou tricar contract
recur big posit settlement all-in expect segment
earn flat y/i
provid color ep reduct relat healthcar servic
busi y/i headwind compani flag earn releas
look similar compani flag earn releas trend
deterior sequenti trend didnt improv sequenti might
expect outlook issu releas
note call pd pharmaci network volum slightli
year versu expect primarili gener compani also
experienc shift market dynam specialti pharmaci busi primarili
around member initi engag new therapi tend fill
third-parti provid rather humana pharmaci elabor
trend compani seen acceler recent quarter note
pharmaci team intent focus improv dynam
discuss initi focus
note call compani make invest conviva
includ acceler rebrand posit busi strong annual
elect period bolster elabor understand
conviva includ four subsidiari mcci medic group cac-florida
medic center continucar medic center metcar florida believ
conviva solut repres nearli physician practic clinician
patient across state texa florida big conviva
revenu much extern custom
views/thought recent propos allow plan
includ telehealth benefit basic benefit versu supplement benefit
estim might cost roughli seem low view probabl
reflect expect low initi adopt among senior guess guy
focus take advantag telehealth remot patient monitor set
etc versu direct consum set-up think right
comment call focus medicaid
term win contract organ necessari appropri
acquir medicaid platform impli compani open larg
scale transact medicaid busi would rather focu state state
tuck-in region local acquisit opportun
expect timelin meddata sale process
give us sens differ busi insid meddata
compet compani like unh optum thc conif
provid servic would complementari compani
may take time redeploy proce meddata sale right
think could take dilut quarter sale becom
net posit contributor capit redeploy
oper improv effici plan target mln
 mln oper improv compani also plan
reach full run rate mln end full run rate mln
oper improv end talk us activ
done project thu far still on-going still
need achiev target
new cfo stephen farber highlight area hope target cost
save futur think enhanc prospect
compani achiev save target cost administr expens
reduct effort discuss last quarter repres potenti increment
cost save may captur longer period time
compani report mention growth clinician compens
expens exist practic provid bit color mean
continu headwind salari expens y/i basi come
youv talk cross-sel opportun remind us
see opportun front
area busi see fastest organ growth vs slowest
guidanc same-unit revenu growth lower would say
significantli driven advers birth trend see obvious
tough comp vs same-unit day grew major
factor well
give us sens seen thu far quarter would
say trend within expect birth continu
weak like saw
long-term outlook respect birth trend perspect
particular reason seen weak recent
given sluggish volum seen particularli request increas
stipend/subsidi client hospit prioriti head
origin got radiolog busi vrad recent
acquir facility-bas practic updat us practic
well integr vrad
long-term outlook same-unit price growth seem like recent
quarter improv due manag care contract
improv believ compon oper improv plan
finish specif activ relat oper
improv plan expect greater weak same-unit price
past year two weve seen neg payor mix trend particularli
around anesthesiolog busi caus shift updat us
pace neg mix shift reach termin level think
soon
asid neg payor mix trend anesthesia busi
busi perform produc reason level volum growth
there discuss rework physician contract appropri
make physician participatori practic success rather pay
fix salari far along type renegoti
approach convers much physician compens across
compani variabl vs fix
think deploy remain mln share repurchas
author someth expect occur rel quickli
pipelin look main acquisit prioriti
increment thought acquisit anesthesia space point
radiolog deal multipl similar neonatolog deal multipl
bit higher also talk multipl synerg
basi nomin basi much typic abl reduc effect
multipl long typic take
decreas leverag prioriti order off-set impact rise interest rate
environ much debt variabl vs fix point consid
lock debt fix rate
two lead competitor asset hand privat equiti
envis seen lessen competit deal
compani properti divers urban market across countri
think tenet portfolio point compani one two
retain market point gener percentag facil
market grow faster nation averag percentag remain
market less nation averag underli growth els would
character market tenet oper tenet find attract
volum trend bounc around industri last year
econom backdrop chang effect matur think
macro backdrop see year respect inpati
recent period outpati recent quarter normal
trend could persist year think normal inpati admit
adjust admit growth look like tenet portfolio
discuss see respect manag care contract
notabl chang expect payment rate term contract
overal rev per adj admit normal ca provid fee
percentag tenet manag care contract lock
recent quarter tenet note capit contract california
experienc advers claim experi drag earn recent
quarter preval type capit arrang tenet
portfolio specif led advers experi quarter
consid unusu type claim experi happen time
time risk claim
volum sluggish across healthcar provid space last year seem
rebound normal histor level marketplac
y/i thought driven rebound
volum year would character year y/i volum growth trend
sustain trend
believ build block develop view sustain
growth rate ambulatori surgeri center busi term volum price
rev per case grew acuiti etc
ytd basi compani deploy roughli mln acquisit
compani target full year outlay total mln would
suggest anticip strong finish term deal deal tend back
end load toward fourth quarter year particular reason would
describ competit landscap deal
unit health enter marketplac year ago purchas
surgeri center america extent entri segment
chang competit landscap term price compet
recent quarterli releas compani note recent purchas
three freestand emerg room texa novemb extent
outpati capabl part busi interest potenti acquisit
target competit type asset less activ surgeri
compani say strateg review process continu
outsid time frame point process conclud
recent confer call compani broaden strateg option
consid includ potenti sale also potenti merger tax
effici spin-off combin altern transact broaden
potenti option make want go back make sure clear view
compani tri accomplish undertak process conif
free capit use pay debt invest higher return area
busi conif go requir capit will
commit think conif could acceler growth trajectori
independ entiti part differ organ
extent conif sale process yield cash parent compani
see prioriti capit deploy current current credit
arrang limit proce gener
mid-point year guidanc tenet project post roughli
ebitda margin year realiz number move part
see normal current ebitda margin level see greatest
opportun margin improv across three major busi line within
busi line margin improv come
see term labor cost wage increas
rang comment see respect nurs turnov
and/or use temporari contract labor overtim
compani look exit year mln cost save run rate
much core run rate much consid
increment tailwind
recent quarter compani note malpractic trend
increment drag result compar year-ago period assum
malpractic accrual made everi quarter driven actuari assumpt
regardless specif claim payment made one quarter anoth
actual payment claim would gener direct impact quarterli
accrual period paid howev seem like claim settlement
occur third quarter enough drive least short term increas
accrual right way think dynam occur
third quarter like drive higher accrual go forward
recent quarterli review tenet highlight restructur refresh
accomplish sinc octob roughli board
chang corpor leader transit new peopl
refresh larg done point would describ tenet board today
compar tenet board prior octob
behavior health busi volum strong clearli
overal market supply/demand busi favor
anyth particular drove strong volum trend
see nice acceler ss volum busi increas lo
pressur impact compani ss patient day revenu quarter
elabor lo pressur saw expect
trend moder next month
past talk potenti abl off-set length stay pressur
observ behavior increas admiss need chang make
happen ad capac staff long take
think past said thought market could support
organic/sam facil revenu growth around updat thought
might abl hit ss revenu growth target
updat staf challeng compani highlight
behavior busi past
one major peer seen staf issu uk know small
portion busi thought see uk labor
market much challeng relat brexit uncertainti around
immigr statu worker outsid uk brexit transit
occur much help expect see wage pressur due
recent salari increas announc nh occur sever year
nh commun whether would increas reimburs rate
off-set wage pressur
updat impact eas imd exclus latest
discuss gener acut care hospit work assum
medicaid adult behavior patient see impact medicaid
volum payment rate
report strong volum trend moder recent
quarter think core ss revenu growth busi go
forward think split volum price
regard core fundament acut care sector would compar
key trend acut care divis today versu year ago
increas consumer greater cost share high deduct plan
impact patient behavior regard util
tradit come acut care busi tend look la vega
south texa major market comment market
trend recent
also recent southern california emerg anoth key market
big market today competit demograph
manag care contract environ chang way last
year updat us commerci contract term
price larg steadi see term shift valu base
see labor front wage turnov product etc
acut care busi comment competit physician acut
care find still consider interest employ
hospit effort simpli recruit doctor refer physician staff
impli ebitda guidanc seem impli flat y/i ebitda trend
discuss put take need consid
discuss capital-expenditure outlook next year remind us
key focus capit deploy year next year
major develop project boost capital-expenditure talk
recent/curr capit project contribution/drag
year
expect next year
result
would gaug level activ acut care psych market
rel peer stand somewhat under-lev thought
leverag go forward fair assum absent deal activ
use buy-back
would like start current regulatori environ telehealth/telemedicin
clearli seen lot regulatori action last month
medicar fee-for-servic medicar advantag well state show
flexibl respect medicaid commerci coverag telehealth get
specif rule regul minut think chang
past year result administr state
lawmak becom support healthcar deliveri platform
respect propos week back final would allow
medicar advantag health plan includ telehealth benefit basic benefit
rather supplement benefit begin talk
would mean telehealth industri teladoc specif
see plan includ telehealth benefit support qualiti score
rate etc start convers medicar
advantag plan mco view telehealth benefit senior
given uncertainti around util trend telehealth senior
concern regard senior willing use telehealth benefit least compar
younger commerci popul think approach health plan
telehealth benefit senior differ approach telehealth
benefit commerci popul
switch anoth major telehealth relat propos includ
physician fee schedul rule final week back expand
medicar reimburs provid remot patient monitor etc understand
opportun providers- focus busi white-label
technolog hospit health system first remind us big
busi right teladoc health seen pick-up
interest health system provid organ sinc rule came
compani highlight new contract win investor day sell
season almost wrap updat seen pick-up
particular type offer
past guy talk compani abl gain close
million member cross-sel up-sel exist client talk
success seen particular type
cross-sel up-sel appeal client
talk surround sound technolog platform well new
digit market strategi explain technolog approach
differ competitor exactli uniqu teladoc health platform
telehealth provid lack
speak chronic/complex care treatment capabl
incorpor diagnost technolog platform allow
teladoc health
talk expect annual util
increas
bp talk potenti driver
respect averag pepm teladoc health talk expect
annual increas primarili driven cross-sel
up-sel exist client
respect partnership expect fulli roll
end provid updat much expect
bp util pick-up attribut partnership
upsid bp outlook
compani fourth quarter guidanc assum pick-up revenu visit
primarili driven season busi major contract
roll like drive increment visit
guidanc assum respect flu season
last quarter guy note compani gross margin like moder
closer low compani gross margin
still right outlook would impli close gross
margin think right think gross
margin trend beyond
done target acquisit last year compani bought
best doctor year june compani close acquisit advanc
medic talk compani acquisit strategi
particular area compani might will explor opportun
supplement strong organ growth
talk betterhelp teladoc health on-line portal provid direct-to-
consum access behavior health much revenu ebitda
busi current gener third quarter earn call compani talk
focu diversifi market channel product discuss
detail
talk opportun intern market
exposur right
provid updat tricar busi roll-out
govern decid slower roll-out strategi origin commun
think live get board
think return profit growth core pharma segment
forecast massiv ramp profit growth explain
primari driver behind
speak factor neg impact profit trend next
fiscal year particular big impact optum repric well
contract repric across market particularli expect see larger portion
contract enter repric process typic year
disclos gener deflat rate combin buy side sell side deflat
one metric right way think definit combin rate
gross profit declin particular basket gener think forecast
combin metric leav room error guidanc perspect
would categor steadi state rate gener deflat regulatori
barrier fda backlog approv influenc buy side price dynam
would say high single-digit even low double-digit deflat sustain
enough manufactur drop market rate
opportun see leverag red oak sourc jv
way add valu strateg partner
besid gener purchas anticip major chang relationship
come renew
trump administr regul continu focu drug price
recent manufactur announc either delay roll-back price
increas implic brand inflat industri
expos brand price inflat thought elect
on-going move away contract depend drug price inflat
essenti compon overal compens pictur give us idea
split overal gross profit gener drug distribut come
fix contract versu variabl pursu corpor strategi chang
mix go forward
go detail global effort roll led larg
inventori write-off cordi prevent similar write-off
talk cordi initi pat holt new head cordi jon
giacomin medic segment ceo type chang expect
much progress made thu far help us understand
trajectori toward profit growth end
latest medtron patient recoveri busi track
products/market perform differ expect
provid updat continu suppli disrupt exam glove
expect subsid speak fundament demand trend key
driver across medic busi
recent divest major interest navihealth pe firm speak
strateg rational behind transact increas invest sort
growth view navihealth achiev longer term given
deconsolid navihealth earn help us think impact
divestitur medic segment revenu earn growth
provid updat debt pay leverag ratio go forward
time share repurchas
think foreign currenc exposur realiz tailwind
recent weak dollar
much benefit guidanc assum new gener introduct
impact gener fda pipelin biosimilar opportun
provid us view potenti impact jpm/amzn/brk ventur
busi industri gener also implic medic
thought amazon recent step drug suppli distribut
servic chain acquisit pillpack
share thought hh propos remov safe harbor rebat
could impact either directli indirectli
implic concept part drug shift part specialti step therapi
indic base step therapi
speak recent acceler test mix influenc asp
expect test volume/pric
attribut revenu slowdown conserv recognit
polici beacon carrier cardio test experienc acceler
expect
speak underli demand trend across market particular
price trend see current see pressur particular
segment competit environ anticip price
degrad come quarter
lt gross margin target break asp cost per test
big salesforc anticip chang
 pipelin look
genet test still earli stage adopt challeng face
compar result other
barrier reimburs competitor struggl
collect rate
expand third-parti payor predominantli cash impact
collect rate
approach reimburs differ peer
help us understand detail intern initi
opportun near term revenu potenti
commerci payor sign date
major new partnership pipelin awar
provid color new relationship might establish
recent
discuss regulatori environ affect go forward
aspect technolog believ difficult replic cant
other thing
market product categori /or custom plan target next
much dental consum growth attribut underli market
dynam vs market share gains/loss see current market
growth rate consum na market
think ramp revenu profit associ
expand relationship approach steadi state
sort visibl underli consum demand trend across
dental busi
note weak germani dental equip explain on-going
regulatori factor expect last
speak henri schein one earli result ventur far
demand gener strategi expand adopt across practic
describ relationship differ across dso henri
schein one fit relationship
provid updat recent ftc complaint alleg price collus
seen evid greater direct distribut
anyth chang increment posit neg relat opportun
sirona relationship rel initi expect
quantifi impact ad xray technolog think
sale mix could ultim evolv product current
speak strength experienc implant term
premium versu valu growth come current
see greatest opportun
speak recent invest three implant busi intra-lock
medenti medic pro-cam competit posit implant
talk recent launch slx clear align system
product differenti product current expect market
plan posit product price
note earn call plan begin market clear align
earli plan provid uptak metric type goal set
believ market opportun clear align segment given
clear domin player space conjunct
least two competitor enter space
amazon lot nois industri whether on-line retail
may provid viabl altern tradit distributor consum side
busi stanc issu amazon market share
seem disconnect number underli util demand
trend medic report attribut share gain
provid color around recent trend medic see major
driver risk factor head
opportun one medic
margin differ medic dental give us sens
product mix medic highest margin product
key driver rel faster growth medic despit low
anim health busi consid compon diversif
strategi especi consid segment leadership space above-
market growth discuss rational behind spin perspect
remain compani word posit
speak propos spin-off subsequ merger anim health
busi vet first choic new compani optim
posit market strateg rational behind merger synergi
manufactur switch direct agenc sale impact segment y/i
growth quit significantli year anticip chang agenc
sale strategi manufactur chang impact profit
exclud impact agenc vs buy/sel contract shift north american
anim health busi experienc quit strong growth y/i recent
quarter think segment growth remaind year
drove strength quarter could put take
growth may may achiev ensu quarter
speak declin intern parasiticid sale
meaning chang relationship manufactur
speak competit posit veterinari practic manag
system tie
note restrict initi use vet first choic
billion payment provid addit color
talk million revenu recogn us depart
defens technolog value-ad servic segment one
larger contract recur project
speak henri schein one drive growth technolog
value-ad servic segment understand joint ventur net-
neutral ep think growth trajectori throughout
top-line perspect think revenu margin
speak go-forward expect minor interest line
youv bought back anim outsid interest biohorizon
busi embed line point profit
youv mention push sell higher margin privat label product talk
associ initi percentag current sale
would character current pipelin across dental medic
gap offer product and/or geograph perspect
think capit deploy prioriti seen
valuat step respect acquisit may look
head toward end speak sort visibl
revenu portion busi alreadi contract portion
busi consid recur speak potenti area upsid
downsid
think inher margin leverag busi model
project bp oper margin expans exclud stock comp
sustain trajectori margin differenti commerci side
busi versu state govern busi much margin leverag
expect outsiz growth commerci side
prospect repeal may remot overal polici uncertainti
neg impact client base delay potenti new busi
midterm behind us overal takeaway state-level
federal-level elect result particularli noteworthi
youv mention commit technolog innov particularli
machine-learn process artifici intellig speak
technolog provid pathway growth think cost
opportun associ technolog
acknowledg provid guidanc suggest fair
assum capital-expenditure remain elev level outsid mainten
capital-expenditure speak make invest hope
achiev elev spend
compani fair amount balanc sheet flexibl net debt ebitda
recent quarter end talk compani appetit
addit leverag view highest prioriti capit deploy
initi mani turn leverag would comfort take
deriv impact relat verita capit recent acquisit
one closest competitor cotiv
coordin benefit
experienc rather larg medicar rac liabil releas benefit
top-lin talk drive build-up liabil caus
subsequ releas liabil releas typic occur first
medicaid contribut substanti amount coordin benefit segment
discuss exposur medicaid program implic
medicaid expans hand contract medicaid program
certainli topic top mind washington
hear medicaid program mention mid-calendar
medicaid expans could shrink earliest updat
think medicaid program
mention call recent legisl pass relat chip
repres increment opportun think
model cob quantifi upsid would opportun
requir sort ramp
recent announc launch intern develop risk manag
solut elli help us better understand product
differenti offer current market acknowledg still
earli day would character custom feedback
discuss market opportun newli launch elli product
plan leverag medicaid expertis understand dont expect
meaning contribut think ramp
speak opportun eliza acquisit eliza member
engag platform fit essett acquisit care manag
much overlap target custom base tradit claim
audit busi popul health capabl youv ad essett
highlight past expect continu double-digit growth
care manag busi eliza key driver busi
pipelin look like
discuss cyclic eliza think revenu
contribut cadenc busi cyclic differ base
busi
eliza perform compar expect sinc acquisit
adjust initi expect busi perform line
eliza salesforc fulli ramp see progress custom
acquisition/expans see salesforc becom meaning
driver growth segment
would seem larg number potenti assets/cap could fit
popul health umbrella defin segment
capabl area your interest biggest gap
custom face popul health member engag perspect
last year revenu impact delay implement process
speak invest made speed implement end
oppos customer-rel delay
quick review speak key factor drove book
strength recent quarter see book progress
remaind year speak mix new client win ytd larg vs
note sequenti ramp offer remain strong
million new busi quarter elabor
combin data offer reson new well exist custom
feedback hear custom
next gen book materi meaning top-line
provid context around fx head remind
us medium term goal term growth rate across core busi
estim million fx headwind confer call
split across segment
oce continu gain momentum speak broader opportun take
share market new relationship roch
mention recent earn call larg pharma renew cycl
provid lot opportun drive greater uptak oce offer
next month talk strategi maxim adopt
would character convers potenti client thu
differenti offer overal market opportun
main competitor compar veeva
talk margin trend segment think
profit
provid updat cost save target
accomplish merger-to-d ahead plan behind plan term cost
synergi run surpris front sinc close
fund environ close tie broader biotech fund
environ see term broader demand trend
percent incom rfp leverag combin offer
today next year percent rfp appli
combin busi help bolster world evid offer
growth rate rwe
contract sale medic solut anticip turnaround near
term specif driver give hope paus visibl
quickli abl
better
enhanc new im global data provid us specif exampl
identifi physician site
provid updat cra retent rate post-merg
stand term virtual trial concept associ initi
place
term prioriti continu tuck-in deal target
area current healthi deal pipelin continu expect deal
add percentag point growth annual estim deal spend
recent rise stock price impact view share buyback
hole fill technolog offer commerci solut
busi describ recent acquisit made year-to-
date relat platform updat de-lever share repurchas
expect meaning step capit expenditur
see hesit across custom base concern around drug
labcorp america lh
give us updat relationship walgreen think
opportun relat recent expans announc near
term longer term
would alloc on-going gross margin pressur pama
reimburs rate offset launchpad initi
track covanc launchpad initi potenti
acceler even increas cost save
expect covanc adj ebit margin reach lt
compar preclin clinic competitor
speak launchpad phase ii focus lcd segment
sort initi plan includ think
capit deploy think weigh share
recent disclos cybersecur breach sort invest
made histor sort invest need make go forward
mitig risk see futur headwind relat breach
give us updat underli fundament util trend across core
clinic laboratori busi metric watch close determin
laboratori volum trend expect organ volum growth
trend progress throughout balanc year
help us think net potenti impact new unit healthcar
aetna contract begin januari put take
relat volum expect price pressur think
time impact
light recent contract announc speak
differenti quest competitor also particip dual-
prefer relationship would doctor prefer send patient oppos
anoth lab prefer relationship quickli shift happen
regard clinic lab fee schedul clf incorpor anoth
round repric quantifi help us think increment headwind
revenu expect
seen compet nation lab servic provid acquir sever lab-
type busi past year havent activ front even
despit increas pressur independ provid hospit outreach lab
pama speak might case view next round
repric relat pama spur activ
comment chang see hospit insourc
outsourc trend would character current pipelin
acknowledg acquisit annual may mt sinai paml
busi track rel initi expect seen uptick
health system interest back deal back regulatori shift
market share vs vs rest market trend time
view trajectori next year
much headwind would say high deduct health plan provid
weve posit clinic laboratori inform technolog play
commod servic provid appropri rel busi
monet vast amount data collect cours
oper lab busi view offer light
data-driven offer marketplac
understand your tri deemphas quarterli btb favor ttm btb
saw pretti signific fluctuat recent quarterli net btb metric
estimate help us understand may driven
weak follow strength
seen one larg competitor cro side busi make
interest move term introduc fix price model think type
model catch industri given thought whether
would consid similar offer
speak win rate well broader price environ cro
side busi
recent acquir chiltern bolster footprint cro space
acquisit add presenc asia pacif previous note
focu area last year result neg impact two larg trial
cancel expand cro asset help smooth volatil
given biotech fund strength first half mani begun
question trend may revers peak speak
seen recent term biotech fund rfp well expect
remaind year
initi place acceler voluntari opt-in clinic trial
databas new busi award covanc relat combin services/data
speak strateg rational behind sciformix acquisit sort
opportun see cro offer pharmacovigil regulatori
youv mention trial leverag combin data asset across
covanc labcorp busi speak custom feedback
offer provid metric help us think support drug
develop process client
walk us key growth driver lt would character on-going
fundament demand trend outlook progress
latest ntp suppli disrupt
expect invest creat suppli chain redund impact
margin timelin reach goal relat effort
speak competit landscap ultrasound contrast market
defin kind opportun view abroad
talk defin european initi progress
see develop defin achiev meaning traction
remind us key patent expir potenti
combat expir anywher envis intens
talk competit threat molybdenum view potenti
impact busi chang
make bwxt announc abl bring
product market
what competit environ xenon recent competit impact
busi opportun grow
discuss contract strategi
nuclear product
technelite/xenon what work chang would make
agreement radio pharmaci group look like scope term etc
talk recent wave key hire cfo head manufactur hr
search new commerci head reflect busi strategi
investor think defin intellectu properti specif
pertain patent expir come year
complet spa fda provid updat
timelin lvef indic defin
provid updat spa work lmi clinic trial
statu clinic trial began june mani patient
enrol thu far still expect finish
new cfo place see becom nearer term part
updat capit deploy initi prioriti respect
 gap offer adjac etc
recent announc multi-year strateg initi conjunct prelim
guidanc broadli detail strateg area focu much expect
reinvest busi well expect initi contribut
recent highlight life scienc initi potenti opportun
effort entail requir increment invest
clearli challeng among sell side appropri model
quarterli earn progress help us frame rel import
bigger move item includ claruson rexal covermym
rxcrossroad msd on-going brand distribut negoti major contract
provid updat contract renew shift trend could
point give confid see success lower margin time
agreement come renew
note capit deploy embed guidanc detail
capit deploy prioriti year shift strategi
mention million spend associ opioid initi
legisl includ million incur discuss driver
spend relat opioid epidem us also potenti canada
think expens onward recur
thought amazon recent step drug suppli distribut
servic chain acquisit pillpack view transact
impact directli and/or indirectli
thought hhss recent propos implement new
price payment model medicar part anticip
particip vendor put take
think foreign currenc exposur
remind us exposur gener brand inflat averag
percent contract base trend walk us
season exposur well
speak recent greater scrutini brand price inflat
outlook brand inflat brand inflat assumpt bake
guidanc could drive upsid downsid
gener deflat trend progress think worst
behind us start see somewhat normal possibl even
guidanc assum benefit new gener introduct
potenti impact gener current fda pipelin
youv note pleas progress initi implement
differenti price base drug class continu work
contract renew abl realiz margin benefit repric
mere partial off-set overal price headwind percentag
distribut revenu yet re-price consist strategi
would propos part price rule impact mck us oncolog
healthmart stand profit driver term contribut
fast grow turnov rate franchis anoth
wholesal grow key custom segment cut opportun
heard time number industri constitu
on-going transit away contract reli drug price inflat essenti
compon overal compens comment bit drive
evolut within contract effort whether reflect fundament
belief inflationari environ drug could chang
ultim see split end preliminari thought around
timelin go effort
think impact work capit gener sourc
revis rad/wba asset purchas deal
mention
claruson leverag scale expand new categori
speak gener perform claruson sort opportun still
announc reduct pharmaci uk discuss
uk strategi
level
reimburs deflat assum guidanc see
remain market medium long-term think better
visibl across uk busi
overal reimburs headwind
canada also experienc meaning reimburs headwind
expect expand upon strategi mitig reimburs
headwind advanc revenu diversif opportun
speak rational behind recent acquisit medic specialti
distributor msd expect bolster infus offer much
expect contribut revenu oper incom
discuss current rfp environ recent win rate
see acceler rfi convert rfp
would character current smid biopharma demand biotech fund
environ given exposur segment
speak natur recent cancel note impact
experienc impact custom decision-mak delay
continu experi residu effect delay decision-mak
first half see delay current
sort visibl intermediate/longer-term goal double-
digit revenu growth initi particular expect drive
potenti opportun larg pharma custom
becom increas focu current dynam smaller biotech
speak current price environ everyon behav ration
differ custom segment
discuss qualiti rfp receiv recent quarter
kind pipelin creat rfp much differ
receiv previou quarter size therapeut expertis custom
mention rel recent look take new differ
type project provid addit detail type client type
busi seek
ebitda margin still remain healthili cro peer gener
guid impli margin contract year-over-year drive margin
pressur think model gross margin sg
near term long-term
plan break net servic revenu pass-through revenu
beyond think model revenu basi
given volatil pass-through quarter-to-quart project-to-project
term central lab busi provid updat
see demand perspect extent demand growth driven
differ book polici compar
impact book-to-bil backlog convers metric
given rel conserv book polici expect industri
standard evolv long term
speak natur new busi win latest quarter look
therapeut custom mix disproport larger contract
influenc new busi win
sever data point track across biotech fund conjunct commentari
industri constitu indic strong biotech fund environ
speak may convert book mayb would
expect see impact healthi landscap
expect custom therapeut mix evolv next
speak current custom concentr portion new award
come exist custom compar new custom
therapeut area focu particular categori see longer
studi start-up time complex therapeut area exposur exposur
influenc backlog convers trend seen industri
discuss key differ exclus full servic
busi model functional/piecem work
full-servic model impact growth potenti long-term
risk appetit moder think limit downsid
busi plan continu see strong book environ
perhap favor seen last four five quarter
point key area abl captur effici
exclus full servic staf start time etc
recent discuss amongst cro constitu valu
add offer circumst would add servic
portfolio despit potenti degrad margin
risk inher full servic model
leverag data asset improv win rate speed start-up
see chang competit landscap your compet
new busi see competitor tabl mayb unconvent
player typic would see specif regard larg cro
tradit focu smid biotech compani
comment unconvent merger across cro space lh/cvd
q/im transact inventiv lh/chiltern affect
main competitor come across central lab side
abl compet rel small central lab lab custom also
previous mention step invest central lab busi
elabor initi think fit longer term
return double-digit revenu growth
current cra retent rate contribut better profit
trend locat cincinnati hurt help
opportun improv effici across central lab busi
guidanc seem impli quit bit margin expans despit headwind
includ hire busi develop invest among other help
us get comfort guid walk us factor would lead
acknowledg guidanc speak quarterli progress
share repurchas activ plan front
product use capit point
histor acquisit could chang
sort opportun see pipelin sort opportun
need see becom interest deploy capit manner
would ever seller obvious right price theori
acquir larger cro exclus full servic would impact
busi model
geograph area focu want exposur
effort bolster central lab busi a/organ
provid updat infrastructur invest remind us
rational make invest time
regulatory/polit chang drug pricing/fda reform discuss might
posit neg implic come discuss
quit bit chatter biopharmaceut space would
busi impact larger custom engag
competitor leverag fix price model attract busi
well drive higher margin potenti view fix price model
cro industri specif someth could offer
dso profil current dynam differ custom segment
character underli demand trend companion anim industri
describ on-going demand shift opportun brand gener
therapeut expect increas traction gener move forward
view role gener anim health
custom acquisit cost continu grow steadili view inflect
point custom acquisit cost stabil even declin
increasingli higher advertis spend per person way sustain new custom
mention call advertis spend rise come quarter
give us sens your spend track compar
expect advertis strategi evolv
speak henri schein vet first choic spin-off/merg would
character threat
gross margin compress recent quarter driven addit
discount off-set competit market strategi go-forward
basi point hold line price
exampl next gener product drove gross margin expans
mention potenti chang direct relationship manufactur
provid detail
talk mobil app improv adopt trend whether
impact revenu
character capit deploy strategi
activ front expect chang strategi near term
point anyth drove moder new custom growth
mention expect increas advertis spend next year
expect market strategi chang kind metric use
assess overal effect roi
experienc impact sale new custom growth given recent
launch petsmart on-line veterinari pharmaci line e-
commerc platform vetsourc vet first choic expect
addit entrant on-line marketplac competit respons
signific consolid across space sever specialti brick
mortar competitor take omni-channel approach particularli
recent petsmart acquisit chewi com expect consolid
continu impact busi
speak on-line advertis strategi purport link opioid
much cut term sg
think increment benefit gain next-gen parasiticid
increas ad-spend posit affect reorder sale new order
type offlin advertis work market hit
flea/tick/heartworm tripl combo benefit busi
character on-going dynam product anim demand trend
differ domest intern market
challeng dairi market visibl might
improv think demand trend across poultri swine dairi
next year
talk foray companion anim come
long work
expect entri companion anim go beyond lyme diseas
project kind project could expect
could provid color invest spend use
commerci sale forc develop product pipelin
product pipelin look
would character underli demand trend categori
headwinds/tailwind incorpor guidanc expect
adjust sg increas last two quarter expect
come period see sg return previou level
expect chang mix profit versu part
world mention unstabl intern econom condit impact
anim busi possibl break fx impact
recent quarter didnt disclos sale medic import antibiot
us sale mia immateri
expect mitig effect antibiot regul potenti
regulatori environ becom challeng us
view intern market pocket strength vs
quantifi exposur viginiamycin
speak acquisit mvp integr progress
grow compar base busi expect contribut move
speak consumer-driven pressur busi
given necess increas protein product emerg market
expect capit strong secular trend plan
intern expans challeng expect execut strategi
comment capit deploy strategi move forward
view current landscap
speak traction omnigen europ china commentari
state us dairi
speak new product current develop key area
invest see meaning opportun certain therapeut class
clarifi impact sale gross margin commod
updat mecadox visibl fda request
traction magni-phi poultri nutrit specialti product
divestitur perform product busi
updat aquacultur initi
feel need scale readili compet companion anim
market compet use one-off product
talk in-licens companion anim technolog
platform complet product readi go-to-market
could provid littl bit color loss distribut agreement
 earli fiscal
think nafta global trade dynam thought
fiscal expect think
exposur
speak recent acquisit vaccin space provid
color could get back double-digit growth vaccin nutrit
walk us bridg initi guidanc basi
updat guidanc basi plan offer metric
basi go forward compar purpos
talk rhetor come washington relat value-bas care
aco mip macra program could initi mean
expect start see impact
benefit seen broader industri consolid
view amazon threat view evolv past year
ampl balanc sheet flexibl net cash ebitda recent quarter
remind us capit deploy prioriti level leverag could
stretch right acquisit
acquir advisori board healthcar divis like deriv
impact much perform servic offer overlap
advisori board abl win busi effect part larger entiti
health system could less like purchas consult servic
subsidiari major payor conflict interest
walk ownership structur differ class
class share ownership structur provid competit
differenti
end control us hospit
trend expect continu exactli think metric
view hospit choos cash
high-valu provid network think said one larg employ
talk health system might disproportion start
direct care think pertain futur incom
statement health system possibl pay sort collabor fee
part model anoth line thought
speak strategi target academ health system membership growth
success penetr feedback hear
product ramp servic implement differ health system
discuss exposur tariff dynam relat intern
trade sourc product raw materi particularli relat china
relat recent acquisit stanson health help us understand
potenti opportun well use case custom
stanson offer differenti competitor
 front key focu area think multipl
marketplac
provid updat recent hospit util trend sort util
expect bake guid
help us think gpo net admin fee growth extent driven
util price much growth opportun within exist client
acquisit post ipo recent bolster presenc
altern site gpo space well specialti pharmaci think futur
opportun signific capabl custom ask
percentag gpo member also perform servic custom
increas time trajectori next year
talk new commit buy program surpass
differenti form program youv mention past program
trend intern expect provid updat expect
surpass drive growth
long-term integr pharmaci strategi expect
busi contribut growth beyond plan use
integr pharmaci offer drive valu custom
give scale quit bit smaller specialti pharmaci
marketplac posit busi gain access key limit
initi guid basi impli quit year-over-year step growth
perform servic segment help us get comfort assumpt
bake guidanc put take guid
recept health system perform servic solut
adopt challeng pushback see market
solut offer tangibl benefit form cost save arent see
go-to-market strategi perform servic solut
health system target get word
implement capac new expand busi seen
delay solut implement due capac restraint
give us idea implement timelin word long
take convert sign contract revenu implement
solut new custom differ exist custom
expand busi
speak regulatori uncertainti continu delay decision-mak
whether expect decision-mak pick pace near-term
view custom need hear order resum normal decision-mak
attribut weaker experi perform servic segment
season ambulatori regulatori report busi talk
season busi think quarterli progress
discuss premier appli scienc help us understand opportun
associ work pharmaceut manufactur
thought hh propos trump initi target drug
price could directli and/or indirectli impact elect day takeaway
provid color see cvs/aet transact affect
perform decis convers payor evolv deal
complet appear increasingli like near term
speak success thu far jv/partnership strategi inher
less capit intens find better traction health servic relat
pilot retail-cent partnership investor get sens traction
thought amazon recent entri mail-ord pharmaci
acquisit pillpack impact seen far entri
transform competit landscape/dynam
deriv impact extern think could see result
broader vertic integr across healthcar continuum
provid updat capit deploy prioriti particularli
relat share repurchas vs strateg
term us sort opportun exist could
attract given market environ strateg look
youv note pressur gross margin like continu
eas remaind speak put
take gross margin view normal margin longer
term follow asset acquisit store optim initi
youv recent highlight notabl room cut sg key driver
sg leverag go forward think line item
remind us impact gener deflat profit deflat
eas mid-to-high singl digit pace seem typic across
industri would impact earn
share thought commentari washington
pharmaceut manufactur relat brand price exposur
brand inflat think affect margins/profit dollar
help us think accret amend transact rite aid
specif expect million cost save million
prior realiz time horizon provid color
ramp save split cog sg
revenu per store much lower wba corpor averag level much
could figur increas sort time frame
think rad potenti wbad particip view
light
provid updat newer prefer relationship
recent analyst day emphas partnership/jvs/collabor
opportun term capit deploy opportun speak
rational plan gener specif help us understand announc
relationship fit overal strategi
speak rational behind creation valoremrx specialti
solut collabor express script view specialti
offer long term particularli conjunct alliancerx
partnership prime therapeut
taken minor interest pharmerica part latter acquisit
financi sponsor speak opportun
specialty/institut pharmaci speak rational
would take minor stake pharmerica oppos purchas busi
outright believ would caus anti-trust concern
compar cvs/omnicar experi
expand upon opportun see partnership labcorp
recent announc partnership expans store nationwid
see evolv speak econom arrang
speak partnership drop pick
servic provid updat traction servic custom
extent servic succeed drive store traffic
expect relationship benefit longer term
humana partner primari partner oper senior-
focus primari care clinic within two store kansa citi
discuss vision partnership potenti opportun
recent announc partnership custom order
groceri on-line pickup order walgreen store speak
longer term vision partnership view relationship may
evolv thought acquir in-stor pharmaci
much fred pharmaci file buy add anticip mani
opportun futur file buy
retail pharmaci wholesal
speak pressur see uk particularli relat
reimburs volum growth view pressur subsid
think part busi longer term
give us thought transact sale guangzhou
purchas guoda china align global strategi
speak intern wholesal strategi benefit
talk put take wholesal segment growth
past sever quarter youv mention past rel difficult
environ continent europ particularli germani franc off-set
strength emerg market speak market exposur
think growth potenti long term
would character current fundament dynam product
anim busi relat contraction/expans herd size feed cost
cattl feed relev variabl think
speci segment next coupl quarter beyond overal exposur
insight consum spend trend given current macroeconom environ
industri trend see current companion anim market
posit vet util trend weve experienc sustain pet ownership
livestock headwind fewer intern calendar day tough comp us
fx potenti offset visibl us dairi dynam
provid updat abaxi integr combin sale forc effort
confer call said abaxi low doubl digit exclud
destock expect trend continu provid
color around kind growth expect region geographi
much impact expect destock abaxi portfolio
beyond
livestock diagnost opportun envis time magnitud
time product current smb pipelin
simparica trio combo chewabl flea/tick/heartworm latest file
approv chanc could approv target
apoquel think opportun aggress price product
quantifi market potenti across acut space under-penetrated
growth run rate
veterinarian prescrib apoquel vs cytopoint
level
cannib seen
thought competit landscap atop dermat view
competit threat kindr product much abl combin
apoquel cytopoint help compet new entrant
top prioriti collabor regeneron mab
quantifi much competit rimadyl impact overal sale
materi potenti offset sort strategi take
bundling/promot standpoint relat rimadyl
speak competit clavamox revolut face
see evolv elabor plan life cycl innov
fostera pcv perform track market share
provid updat pharmaq underli fundament across
aquacultur opportun recent agreement pharmaq
vinh hoan vietnam
altern antibiot product explor potenti non-antibiot anti-
infect peptid stand develop process
much dollar go novel therapeut vs life-cycle
geographi see largest opportun near term companion anim
product anim altern area deemphas part
restructur initi
takeaway usmca implic broader global trade
australia see market improv near term year drought
repres increment opportun market turn
vfd compar european regul expos
product explain regulations/dynam occur franc antibiot
expect gross margin dynam confid remain
bp margin expans
structur initi ahead plan progress front could
offer profit upsid nearer term
upsid downsid risk guidanc relat cost structur initi
margin go long term
speak rational behind use distributor vs direct sale forc
certain product recent switch distribut vaccin
continu abaxiss plan go direct exclus leverag
distributor dognost
pricing/exclus relationship larger chain distributor particularli us
updat relationship corpor account
thought vet first choic henri schein spin think
potenti evolv suppli chain pet medic consum well
veterinarian choic think broader implic
newer concept rang price realiz longer term
de-lever aggress share repurchas million
 near
expect broader industri consolid anim continu
expect competit landscap look like near term longer term
chang landscap ipo bi/sanofi merger impact
creat new opportun challeng sale forc execut defect
work capit improv near term address high inventori day
sap implement influenc
acquisit nexvet biopharma
discuss leverag mab develop platform
impact regeneron collabor
frame market opportun chronic felin pain nvet
contribut front could peak sale potenti product go
comment licens agreement non-exclus right
certain anti-ngf patent agreement structur expect
benefit develop futur sale lead product ranevetmab
speak benefit platform technolog mab
key area interest regard research collabor
genentech provid financi detail potenti contribut
newli establish relationship continu zoeti
updat partnership zenoaq still expect usda condit
licensur also character market opportun anti-pd-
treat variou form canin cancer quantifi market opportun
updat current expect product receiv
rational behind deal think impact on-going
develop product name could expedit
charl martineau univers toronto compani mention price
labcorp america lh
